EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One
2 hr 5 minAudio
A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it is ready the science has moved, the money has gone somewhere else, and nobody told them the fund they were preparing for creates companies out of raw material. Marie Schroeder is a Principal on the Seed Investments team at Novo Holdings, the investment company owned by the Novo Nordisk Foundation. Before that she spent five years at Novo Nordisk in cardiovascular drug development. Before that, a doctorate at Oxford and research work in Toronto. Beginning with what a seed investor watches at the start of a year, the conversation becomes a practical guide to building and funding early biotech: the question her chief scientific officer put to every project until it hurt, what to do in the first hour after a negative readout, why the founder who discovered the science is often the wrong person to run the company, and how her team tracked one Swedish heart failure company for three years before a single risk cleared and the money moved. WHAT LISTENERS CAN EXPECT TO LEARN Why defining what good looks like before the experiment runs decides whether a failed program gets funded twice How to break a plan into killer experiments so each tranche of money buys one specific answer What a board wants to hear on the day something fails, and how early it wants to hear it Why team quality beats science quality in early biotech, argued on commercial grounds What a seed fund actually wants in a cold approach, and why a rejection is usually about timing BEST QUOTES (00:14:09) "Defining what good looks like before you start the experiment is absolutely paramount." (00:22:42) "The target failing is one of maybe five things that could have gone wrong." (00:52:36) "He only has time to give the negative feedback. Every other paragraph was good." (01:15:58) "You can have great science, and if you don't have the right team, it will fail." (01:35:47) "I would rather somebody send a rough concept than spend half their life making a pitch deck." TIMESTAMPS THE YEAR AHEAD (00:00:00) Intro (00:02:35) What is on top of a seed investor's mind this year (00:05:43) The muscle loss problem inside the obesity story RESILIENCE AND FAILURE (00:10:45) What resilience means to a biotech investor (00:14:09) What does good look like, the question behind every project (00:18:42) Killer experiments and what has to be true next (00:22:03) The first hour after a negative readout (00:27:19) Learning resilience without joining Special Forces FEEDBACK, BOUNDARIES AND BAD NEWS (00:45:52) Compromise, burnout and anger out of proportion (00:51:18) The Oxford professor who wrote nonsense on the draft (00:57:25) Jensen Huang, no firings and torture them to greatness FROM OXFORD TO NOVO HOLDINGS (01:02:15) Academics are the true scientists, the belief she dropped (01:07:51) Novo Nordisk, Novo Holdings and the foundation explained (01:12:26) Two lessons from five years inside Novo Nordisk WHO BUILDS THE COMPANY (01:15:49) Why diverse teams are non-negotiable in biotech (01:21:31) Why the scientific founder should not be CEO GETTING FUNDED (01:33:54) The minimum a cold pitch deck needs (01:39:55) The company they watched for three years (01:50:46) Venture capital as a self-fulfilling prophecy WHAT COMES NEXT (01:55:13) Two directions pharma has to run at once (02:01:28) Closing thoughts Marie Schroeder at Novo Holdings: https://novoholdings.dk/people/marie-schroeder Newsletter: https://lsg2g.substack.com/ Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Christian Soschner90% of startups fail. And in drug development, the number is even worse. Most molecules never leave the laboratory, and the few that reach a patient take 10 years of somebody's working life to get there as a minimum.
Marie SchroederParticularly in the therapeutics drug discovery space, um bringing a product from idea to market, if everything goes really, really, really well, which it never does.
Christian SoschnerUm I mean that's a the standard advice for a founder facing those odds is to prepare, build the team, polish the deck, wait until the story holds together. Marie Schroeder invests at the earliest stage there is, and she wants the opposite of that.
Marie SchroederI would way rather have somebody send an unpolished, unfinished concept than spending And the part I did not expect came later.
Christian SoschnerHer team tracked one Swedish hardfair company for three years without putting in a euro. What changed was not the science, and it was not the pitch. A single risk cleared then the money moved that quota.
Marie SchroederBut you can have great science, and if you don't have the right team, it will fail. Um you can have mediocre science and with a great team, actually.
Christian SoschnerMarie Schroeder is a principal on the seed investment team at Nova Holdings. Before that, five years at Novonaudisk in cardiovascular drug development. Before that, a doctorate at Oxford. I ask her about the question her old chief scientific officer puts to every project until it hurts. I ask what a bot wants to hear on the day an experiment fails. I ask why the person who discovered the science is so often the wrong person to run the company. If you build in biotech, fund it, or you have a bot seat, these two hours change what you send an investor next.
Christian SoschnerWe recorded these episodes as a live stream in 2025, and this is a replay. Enjoy the show. It's the first live stream of this year, which is uh extremely, extremely great. It's always amazing that how how fast time flies and how uh how quick 12 months uh can can pass. And uh the uh New Year's Eve is always the time for newest resolution and looking ahead. So I thought we start the first podcast in the new year.
Christian SoschnerUh, with my first question to you coming from the resolution side, you work at uh Nova Holding, are an investor, venture capitalist, and have a lot of insight into the biotech industry. And my first question to you is uh, what's on top of your mind for 2025 when you look uh into the next 12 months? What are you thinking about?
Marie SchroederIt's a great question, and uh, as you said, a very timely one. So um um I'm I'm as you said, an investor at Nova Holdings. And before moving into the investment space, I was a scientist at Nova Nordisk as well. And as we're all aware, um there's considerable activity around um cardiometabolic therapy. So ranging from precision cardiomyopathy um kind of therapeutics with advanced modalities, which is something I'm very passionate and excited about, ranging from, you know, how do you actually improve distribution and sort of get obesity therapeutics to as many people as possible and everything in between.
Marie SchroederSo I think that's certainly at the very top of our list in considering how to actually make these investments in a considered and thoughtful way moving forward. Um, and then yeah, many of this, the questions that we um encounter every year. So the question of how do we build new technologies um to drug the undruggable space? Um how do we it how do we start to regenerate tissues? Um, how do we deliver to to various organs throughout the body with some specificity? So it's definitely a range from, and as a seed investor, of course, we're very excited about the very exploratory and novel and potentially disruptive therapies, but of course, we're also very keen to understand um the exit market and what will what will happen to the more the more late-stage products that we're working with as well.
Christian SoschnerIs is uh out of curiosity, is opacity sense uh a hot topic? I thought everything's solved. You have a product on the market. Um, also no one disc has a product on the market. Uh Ala Lily, I think Rosh is also working on something or has already approved. I thought it's all already solved. Are there still some points open that we need to tackle?
Marie SchroederYeah, absolutely. Another great question. And um there's no doubt that um that the Incretons are fantastic and basically everybody has one or two, or you know, 10, um, and the next generation, the more convenient products, etc. But I think it's also important to remember that obesity was not a thing until about, I mean, less than two years ago, it sort of exploded out of the blue with a with a kind of um success rate that even Nova Nordis couldn't anticipate. It's just, it was just such a huge thing. And so given that there's basically one product that's come to the market, of course, no, it's not solved.
Marie SchroederAnd of course, as in every other therapeutic area, there'll be room for many, many other products. And um, we can talk to this in more detail later on. But just off the top of my head, I mean, of course, production and availability is number one challenge along with cost of goods. Um, all three of those go very much hand in hand. But then beyond that, if you look at the actual therapeutic itself, um, of course, there are some tolerability issues in many people. Some people still don't respond. Um, and there's still parts of the obesity uh treatment paradigm that are not addressed yet.
Marie SchroederSo things like muscle mass. So we all know that when you lose weight, you lose both fat and muscle. And the more weight you lose, the more muscle you. So are we just deferring the obesity pandemic or epidemic to uh, you know, sarcopenia epidemic? And um that's so that's one of the major issues, I would say. Um but yes, so I think the obesity problem is actually just been defined as a problem. So there'll be lots of room to continue to solve it over years to come.
Christian SoschnerThat's good to hear. I'm personally very happy that uh it's allowed to talk about obesity and uh that the population has become health conscious because I think it's the root cause of many diseases. Simply uh if you can so if you can solve that one, I think we can solve many, many more diseases down the road.
Marie SchroederI completely agree. And um, it's actually been a really fun exercise in the last year or so when we're doing due diligence and and talking to experts in the obesity field around some of the opportunities coming in. Um, we I had this one fantastic call with one of the sort of pioneers of obesity as you know, a disease area. And I think he he was one of the PIs on the first clinical trial of looking at obesity as actually a health concern. And he had written a book, you know, in the 90s and had all this controversy around the title because he called obesity disease and the when you know nobody liked that.
Marie SchroederBut this was here was a guy, you know, approaching retirement, and he was just like, I've been saying this for 20 years, look, I'm finally right. And he's it was just such a fun, funny conversation. So yeah, I again totally agree with you.
Christian SoschnerYeah, I remember that uh uh obesity is a problem. You can't say that.
Marie SchroederIt's not yeah.
Christian SoschnerUm let's move forward, let's uh switch obesity to later. I think we have it in part three of the podcast. Uh, my next question to you is uh for the audience on LinkedIn and other streaming platforms today who listen in on the live stream. Uh Marie, when we look at the podcast at the next two hours, what are the three key messages that you want to bring across and why should people listen?
Marie SchroederYeah, so that's another great question. And I probably should have prepared this beforehand. But I think one um It's a surprise question.
Christian SoschnerIt's a surprise question.
Marie SchroederUm, but I I think um one key question um or one key message that I hope we get to today is that venture investing, especially seed investing, which which my team is specialized in, is an exercise in looking to the future. And so um I think one of the discussions that I know we'll we'll have today is what does what does the sort of cardiometabolic and you know advanced therapeutic space look like today, and what will it look like in 10, 20, 30 years, which is basically our job is to predict that and then put a plan in place to try and get there.
Marie SchroederUm, so that discussion and and kind of contemplating what health looks like in the future is something that I'm really looking forward to over the next two hours. Um, I think the the other two topics I'll try and make a little bit more personal and maybe less about the actual investment space and more about um kind of uh professional journeys, if you will. So, one point that we'll talk about in some detail is how personal experience, personal adversity, kind of your own personality is actually really, really important if you want to go down the track of investment, of entrepreneurship, that kind of thing.
Marie SchroederBecause there's just no question that if you're an entrepreneur, if you're trying to start a company, if you're trying to help grow and shepherd, you know, baby companies into unicorns, it is a huge exercise in resilience and persistence. And you're going to hear no, you know, six million times more than you're going to hear yes, yes. So you really need to be able to deal with that. And and um yeah, and of course, that is not just a professional exercise, that's also a personal exercise. So we'll talk about that for a bit. And then the the last topic I think is again um sort of on the on a similar, maybe a related idea.
Marie SchroederUm, and that of course is bringing diversity and um a diverse perspectives, diverse genders, diverse types of people into the investment space. So um of uh this is a topic that's that's discussed at length by many people. Um it's obviously very important to my heart as a woman in the VC space, um, where you still, particularly in biotechs, you still you still see very, very uh male-dominated culture. And I think bringing female and other diverse perspectives um is is just the next thing that needs to happen.
Marie SchroederAnd so we'll discuss that as well.
Christian SoschnerLove it, love it. Three very important topics. And let's start with the first one, with the middle one, um, resilience. Uh, I think it's uh 12 years ago when I did my coaching uh uh education. I heard this term for the first time, I have to admit. And it was so funny. Uh woman was sitting next to me, and we had this exercise that uh we have to tell the other person what we admire in them. So it was uh midterm. Uh I think it was after uh two years and another two years for a lot of three years. And she looked at me and said, I admire you for your resilience.
Christian SoschnerBack then it ran a lot of marathons. And I sat there and said, What does she mean? What does she mean? What is resilience? What is resilience? And uh I didn't know what this term means. Maybe we start uh the first part with uh your interpretation of resilience. What is resilience for you?
Marie SchroederI think resilience is the personal strength and a personal willingness to fight, of course, respectfully, um, I mean metaphorically, fight for for what you believe in. So um to identify a goal and to pursue that goal despite adversity, despite you know the problems that inevitably arise, and um really be able to focus your efforts uh in one direction. And of course, that that isn't um uh with blinders on, of course, that's not excluding outside perspectives.
Marie SchroederOf course, you want to bring those in as much as possible, but it's really just this willingness to hear no, to have setbacks and to sort of get back up again and keep working towards towards your ultimate goal.
Christian SoschnerWhy why is that important in entrepreneurship and investing?
Marie SchroederI think because it's really, really hard. And I think particularly in the therapeutics drug discovery space, um bringing a product from idea to market, if everything goes really, really, really well, which it never does, um I mean, that's a 10-year exercise. So I think even if everything goes perfectly, you still need to be willing to do the hard work day in and day out for 10 plus years. And then when you consider what a complex, multidisciplinary and difficult um industry this is, you will inevitably have failure.
Marie SchroederSome of your experiments won't work, you won't know how to interpret data. The molecule make what you make will have sort of off-target TOX effects that you, you know, you didn't really factor in. You can name a hundred different things that will go wrong, and you can look at, you know, well-published probability of success criteria for a molecule that actually gets to phase one, which already takes out quite a lot of the risk of drug development. So you will inevitably have problems. And if you just freak out and say, oh my gosh, this is never going to work, it's there's no point in even trying, really. It's about kind of being as informed as possible, um, kind of understanding what the problems are.
Marie SchroederWhen, you know, obviously take your take your defeats, take your take your mistakes and learn from them, but then get back up, learn how to fix them and keep going. And then when you add the complexity of the science to the need to actually uh for an entrepreneur to fund all that work, um, you it's not even just about getting the science to work anymore. It's about convincing a group of investors that, you know, are trying, they basically want a guarantee of a 10x return in an industry that's where that's completely impossible. So, how do you actually convince people to sort of go on that journey with you?
Marie SchroederIt's just so many reasons why you'll have a bad day and why you'll want to quit your job, but then ultimately you need to have the vision and passion and resilience to keep going.
Christian SoschnerA question popped to my mind. Um, you said uh resilience for you is uh to focus on a goal and to push through setbacks, uh, especially in biotech with tox effects. Um, and I totally agree to that. The but the truth is, especially when we look at biotech, uh many, many molecules won't work and don't work. And the question that um I like uh meditating over is when is the right time to say no and to stop pursuing a path because it will never work, and when is it too early?
Christian SoschnerDo you have uh ideally a checklist of five parameters, uh of five criteria where you can say one, two, three, four, five? Uh, when this happens, I say no, I move on and I quit. And if that doesn't happen, I move forward. How do you handle that decision?
Marie SchroederYeah, and um I think for every case it's it's different. So we don't have like a uniform checklist that we need to address, um, but we do, but it you're absolutely right that we defining what good looks like before you start the experiment is absolutely paramount to actually making the right decisions moving forward. Um, that's something I learned in in drug development at Novanordisk. I heard that from from Marcus Schindler, the current S CSO, kind of constantly, you know, that was the question you're all the projects would get. What does good look like? What does good look like? Which is a surprisingly difficult question. But it's it's just absolutely essential that you um, whether it's what whether it's medicinal chemistry defining this sort of aspirational, you know, product profile beforehand, so that you hit certain parameters, whether it's a phase one and you need to make sure you have target engagement, that your safety tolerability look like this, it's always about defining what you want to see beforehand and making sure that you you come very, very close to hitting that goal.
Marie SchroederBecause it's so easy when you've, you know, you've spent a few million, 20 million, 30 million dollars, you put so much time and effort and you're so passionate about the project you're pushing forward. If you cut, it's so easy to sort of take, you know, maybe you didn't hit the pre-specified goals, but something good happened and you can kind of reframe the whole, the whole thing. It's so easy to do that. And and of course, you know, when when you've developed your your baby kind of, of course, you want to do that, but that does not make for a good investment decision. So it's really, it is about making the checklist on a case-by-case basis for each stage of the project that you're working on, you know, at the appropriate level.
Christian SoschnerHow does that process look like at uh Nova Holding? So when you invest, my interpretation is when you invest in a company, uh you define for yourself internally your preferred outcome at the end of the day. Um and then measure what happens in reality um compared to your preferred defined outcome. How does the process look like at Nova Holding to really come to this uh preferred or desired outcome?
Marie SchroederYeah, so it's a great question. And um just to give um to qualify my answer a little bit, I work so Nova Holdings has a number of different investment teams ranging from seed stage all the way through principal investments, um, planetary health, et cetera. So each team has very, very different processes um consummate with the stage of the kind of companies that they're working with. But for our seed stage team, um the process, it is kind of what you described. We, of course, you know, come across an interesting company or an interesting concept where we might want to build a new co um with bringing in certain people and certain resources.
Marie SchroederUm, and and of course, the vision is kind of what motivates early investing, right? I mean, you you sort of invest knowing that there's going to be a very high attrition rate and some things might not work. That that's a that's a given, that's part of the game. So you don't even, I mean, of course you worry about that and you you try to put a plan into place, but it's the vision that motivates you. So whether it's um you you are so we had a company um that just announced their uh a 90 million Series A fundraise um the uh the other day uh called Orbis Medicines, where they're making macrocycles to sort of hopefully be able to develop oral versions of biologics.
Marie SchroederIt's it's a very, very exciting company and we're we're super happy about it. Um but this company, it started with some ideas. We created it internally and incubated it and the vision of being able to solve a huge problem in drug discovery, that's what motivated all the work over you know the next the next few years. Um, and so that's that's step one, define you know, what problem are we solving and how does this change change the world in some capacity? But then of course, we need to also be realistic. And for that sort of platform-based company, it's really, really hard to define what what criteria and milestones will hit when.
Marie SchroederBut of course, we try to do so to the best degree possible. With the more convent uh conventional sort of asset-driven company, it becomes a bit easier because, of course, you can make it charts with, you know, if I and D enabling studies go well, they should end around this date, first patient dosed around this date, phase one concludes around this. Inevitably, everything is delayed, but at least you can sort of see the path and you can know when key data readouts come out, and you can kind of define um through milestones and um tranching of your investments, kind of where are the key value inflection points, what needs to be true before the next thing can be true, kind of, and where are you actually significantly de-risking a concept, um, which at the same time, of course, builds builds value.
Marie SchroederSo I think we do a lot of work as because we are uh kind of company builders and we are very hands-on and operational with the companies we work with, we sit down with the founders, with the academics, with with the people that will ultimately go into the company. And we take a lot of care in either reviewing or building these plans, defining what the the sort of you know, killer experiments is the industry term, what are the experiments that will either prove or disprove that a certain risk is a problem or not? When do they fall? When do we expect the data?
Marie SchroederHow much money does it take to get there? And then, you know, we'll start putting in the next money. So we we try to just break things down into sort of the component parts. What is the most important thing to show before the next thing, before the next thing? I think if you start with a, okay, we're we're going to invest in this, you know, this there's this really new new target spun out of Harvard, and we want to make this into a sarcopenia drug. There's a really, really long way in between those two things. And saying, here's 100 million, go do it is not not the solution.
Marie SchroederThat is not money well spent. But putting saying, okay, it's going to take $5 million to get to individual proof of concept. Let's start with that and then kind of evolve from there. That's that's kind of how the process works, if that answers your question to some degree.
Christian SoschnerYes, yes, yes. It's it's always so funny. Uh, not what you said, but uh personally for me. Uh, when we talk uh resilience through logically, it's it's always easy. So we can really come up with the plans. And marathon is for me the best example. So I did 17 marathons uh about 10 years ago. And the funny thing is what you described for business, you can also apply to any other area, like especially sports, can really sit down and say, Okay, when I run 42 kilometers, I know myself. So the first 10k will be funny, the second uh 10k up to the half marathon will also be fine.
Christian SoschnerThere are a lot of people usually on the half marathon distance, and then from kilometer 20 to 30, it will mostly be empty because uh most people stop at half marathon, and only a few are so stupid to uh do that, except the professional runners. And then you know that uh theoretically, between 30 and 40k, you will have a lot of problems, you have to prepare your mind for it and work through. In theory, it's always easy to describe, but then you start the game and then you come to the situation, and then you come to the problem, and you really realize boy, this is really hard.
Christian SoschnerAnd quitting would be so easy, especially when, for example, running a marathon in Vienna, oh, there is the subway station next around the corner. You know, but we see it, and I know I'm home in 10 minutes. Uh, and why should I run the next seven kilometers? And in entrepreneurship, it's pretty much the same. Um, my question to you is um, when we look at the emotional side of resilience and what really happens in people when they play the game, when they are in the game. Um do you have uh from your experience, how do you handle such situations?
Christian SoschnerWhat's going on inside you when you say, okay, I mean, we defined the problem, we knew we we can hit it, but then you are there, and then you have to convince people to stop or to move on and or to change everything around. How do you handle the emotional side?
Marie SchroederYeah, and it's a it's a it's a really, really good question. Um, and I think so. For one thing, I think that the um entrepreneurs who are serving as CEOs, kind of C suite of founders of companies, I think to get that far, hopefully they're pretty, they're pretty good at it already. And they have some emotional coping strategies that they can work from. I think from my perspective, what I would advise and what I've seen work very, very well is if you have a um if you have a sort of negative readout, if you have some sort of negative experimental result.
Marie SchroederThe of course, the first thing you do, you know, your heart sinks, you feel sick, you're really grumpy, you know, you go home, you're in a terrible mood. Fine, you know, ride that out for a little while. That's okay. But then you need to find out exactly what happened. So why did the experiment fail? If it's a clinical trial and it was an adverse effect, what actually happened? And so dissect down what was observed, you know, what the phenotype was, what the result actually said. Then you need to dissect, take another step back. Okay, why would that happen?
Marie SchroederSo what are the various mechanisms that could have brought us to this result? You know, what could have gone wrong? And inevitably, I mean, when you actually think about it, the drug or the target failing is one of maybe five things that even in a pharmacology experiment could have gone wrong. It could have been the molecule, it could have been bad exposure. There are many things that that could also be the problem. And then it's about figuring out, okay, so now I know the potential options that could have contributed to this adverse result. Now I need to eliminate them one by one or you know, figure out what combination of these actually contributed to the wrong answer.
Marie SchroederUm, and another um for aspiring entrepreneurs, having the dialogue with your board kind of as early as possible is really, really important. Um, what boards do not want is to be hit in the face with, oh, there's a catastrophe. Uh-oh, you know, like that, that is not helpful for anyone. They need to be told upon the earliest observation and they need to be fed information so that there's a sort of symmetry of information between the company and the operators in the company and the board who are there to provide, you know, sparring and to provide guidance and input.
Marie SchroederUm, so yeah, calm down, figure out what the problem is and what the potential options um for contributing to that problem are, communicate your what happened and your thinking so far. And then just, you know, systematically, we're we're many of us are scientists at the end of the day. So, you know, apply, you need to take the emotion out of it and you need to figure out what the problem is before you um, yeah, before you kind of freak out and before you sort of communicate externally as well. So don't, you know, don't throw the baby out with the bathwater.
Marie SchroederThat's a terrible American expression that I've never used before. But fundamentally, you need to understand what not just what happened, but what the fundamental problem was and how and if you can de-risk it. Yeah, so it's really to make sure that you know the mental preparation you did when running the marathon, that you've done it, that you trust it, that you kind of rely on that when the emotions start to go a little bit haywire.
Christian SoschnerOne question popped up in my mind while you were speaking. Um calming down. Um it's easy said. Do you have a strategy? Do you do you have a special practice uh that you can recommend uh when emotions hit? I mean, a negative readout is a negative readout, but many people in reality, many people worked usually day and night to get to that point and invested a lot of time. And people are usually happy when uh the end result of work is success and not failure, and then you get a negative readout, and sometimes it's really devastating, and you know now the show is over because this cannot be undone, and there is no way around, uh, and then emotion hits.
Christian SoschnerUh, calming down is always easy said. What's your strategy to calm down?
Marie SchroederYeah, so I think fundamentally what you need to do is take yourself out of the problem and you need to sort of change your mental state. So, whatever that is for um for all of us, and different things have worked differently for me at you know, different points in life. So um exercise can be so probably that's a good time to run a marathon. Um, I I um have done a lot of um Ashtanga yoga in the past, so that really helped me because you're really, really like running. You're very, very focused on the physicality of what you're doing, so it can kind of take you out of a spinning mental headspace.
Marie SchroederUm, watching a sort of, you know, your favorite movie that's like easy and light and fun to follow that that helps. Spending time with friends and family, going out for a glass of wine, all of these things have helped me in the past when you really need to just take your head out of the problem. Um, my my mind starts to certainly when I'm in a negative place, it starts to spin. And I, you know, the the anxiety kind of thing starts to happen where you just imagine every terrible eventuality kind of happening all at once. And you just need to shut that off and whatever works for you.
Marie SchroederBut staying in that place and trying to solve the problem when you're in that mindset is a it's just a total lost cause. You need to do something to change your mental state, hopefully sleep for at least a night, and then the next day you'll be better equipped to start breaking down the problem, figuring out that, okay, probably this sometimes it is, you know, a total deal breaker. If a phase two trial fails, it's the only asset in the pipeline and there's just nothing to say. I mean, then it's about okay, what are the options? How do I sort of deal with the company in a way with integrity and kind of manage this window?
Marie SchroederBut again, you need to sort of break that down step by step and start taking the relevant actions after you've sort of slept and cleared your head.
Christian SoschnerYeah, good points, good points. Uh, when I talk with uh people who were part of uh special forces and are now my age, you're around 50, and they ask the question uh yes, okay, it's logical, and then you have your practice, but how can you learn that actually? And can the the Greenans say, Well, uh join special forces and say, Well, go figure, I mean I'm 50. How should I do that? Or some people in the 30s who are not in the army um have no chance to join special forces and get exposed to a lot of hard situations uh to learn to understand themselves better, their reactions, their responses, and uh refine that.
Christian SoschnerUh, how did you learn to become more resilient in your life, uh in your personal life?
Marie SchroederYeah, so um many. So unfortunately, I mean, for me, I I think so thinking back over my career, so um, and if you think back into, you know, when I was in high school at university, I was always very academically talented. So I was um, I never really had any problems, you know, like my family was was lovely. I did well in school, I played sports, I got into the university I wanted, I did the PhD that I wanted to do. It was all going great. And the first time where I really had some sort of setback was, you know, I was applying, I think, for an NIH career development grant or something like that.
Marie SchroederAnd um I didn't get it, and it was a shock, and I was just horrified and I didn't know what to do. And that actually caused me to spin and I felt quite, you know, detached from my career plan. Everything kind of fell apart for quite a while because I didn't really have any strategies in place. So that that was, I didn't really learn from that. That was just when I didn't have the strategies in place, I couldn't really move forward productively in my career. Um, and kind of during that time, um, I had quite a negative experience where um my my son, this is such a weird thing to have happened, but my son, who's now, you know, about to turn 11 and is a wonderful child, his dad actually, we were living in Denmark at the time, and his dad actually just took him back to Canada without telling me, which was like quite, you know, and it was quite traumatizing.
Marie SchroederSo we essentially kidnapped him. And this was a terrible thing to have happened. It was extremely traumatic for me. I had no idea what to do. Of course, you know, my my son was two. He was just, you know, it was just terrible. Um, and but at this this time, it was there was really no question with what my what the vision was. You know, I was a mother, I loved my son, I needed to be with my son. So there was no question about the where I needed to go. And the fact that there was a big, you know, major, major traumatic setback in that. I mean, who cares? There, I just had to get through it.
Marie SchroederSo, of course, um, so this is um fortunately or unfortunately, where I really learned how to be, you know, how I really built faith in myself that I was a strong and resilient person. And the process here, you know, of course, freak out, you know, obviously. Um, but then it was really building, it was leveraging my network. So one of my best friends at the time knew someone who knew someone who was a um worked at a top family law pro uh firm in in Toronto, which is where my my son had gone, had been taken. Um, I called them, they, you know, kind of knew what to do.
Marie SchroederWe I worked with them, took their advice. So that was like the KOL diligence process. You know, I actually found the team that I wanted to work with and um, you know, found the legal structures that we could use to make sure this was rectified quickly, um, and which which there did exist, luckily. And within about three months of this horrible thing happening, my son, there was, you know, a legal decision in in Canada brought on by the fact that I had found this this amazing firm of lawyers that meant that my son could kind of come back and and you know, resume the life that we had before, which is for better.
Marie SchroederObviously, there were some problems before, so there was still a lot to overcome, but at least the major hurdle was sort of reversed. And I think um going through that was obviously terrible and something I would never ever want to go through again and will never have to and would never wish on anyone. But looking back um eight years or whatever later, I'm I'm really proud of how I navigated that. And and when I um, of course, over the last few years, I've had major career decisions, big pitches to you know, governance committees. Um, I've had to go in front of our partners, you know, at Nova Holdings to pitch new investment decisions, et cetera.
Marie SchroederAnd all of these, I mean, I have no fear of public speaking. I have no fear of failure or setback because it's sort of like, oh, well, did your son get kidnapped? No, okay, you'll probably, you know, if it goes badly, he'll probably live. It'll probably be okay. And so having had that horrible experience, it really makes me know my strength and it makes me really confident that I can, even when I find, you know, yet another new problem that I don't know how to solve, that I will be able to get to the other side of it using um my my personal strength, my motivation, my intelligence, but also the network of great people and trusted contacts that I have around me.
Christian SoschnerAn impressive story. An impressive story. Um how how was that for you back then?
Marie SchroederHow was it for yeah, yeah. Yeah, it was really um, it was it was really terrible, actually. Um, but uh that's uh that's an easy one to say, but I'll um try to find some some silver linings actually. So I think the the benefits of um you know this happening, and which I even kind of felt at the time was that I mean, when you're the mother of a two-year-old and you're trying to figure out your career and your next steps, and it's a very difficult time in any woman's life for sure. But this process, it made me really sort of sit down and think about what do I want my life to be?
Marie SchroederYou know, it because at this point, you know, this horrible thing had happened. If I didn't want to be a mother anymore, if I wanted to go on with my career, I mean, I fully had that option, and maybe that would have been, that would have been the easier option at that time. So, but I really could think about, you know, what do I want from my life? How do I value and prioritize motherhood, my family, my career, et cetera? What do I actually want my life to look like? And it was a really great time to sit down and actually prioritize my life and to figure out how to live with intention. So really to kind of start, start focusing on what I want to look my life to look like.
Marie SchroederHow to, you know, people talk about like manifesting their goals and vision, but it was really maybe the first time in my life where I had sat down and thought, this is what I want to have happen. This is what I want to achieve, and I'm going to work towards this vision. And that's um, and it also was a time where I actually started to trust my instincts and sort of trust myself more. And I think a big reason why I had gotten into that problem is because I sort of didn't try, I could tell there were things that were wrong. I didn't have faith that I could, you know, be a single mother before that. I really I just doubted myself.
Marie SchroederAnd so having been through that horrible trauma, I mean, then I sort of knew, you know, actually I can do anything I put my mind to. And during that time I had these wonderful memories of um spending time with my son, you know, for the first time after I had not seen him. I had never been a day apart from him and then, you know, didn't see him for something like two months. And then, I mean, it was just the the being with him at that time was one of the happiest moments of my life because my sense of purpose was so focused. And I just knew what I wanted to achieve. I knew how to get there. My family, my mom in particular, particularly was so supportive of me that those and my I had some really terrific friends who were also very supportive.
Marie SchroederAnd those memories of just you know solidarity and working together towards a common goal were were kind of priceless for me and really began to set the course for kind of the next phase of my life.
Christian SoschnerYeah, well done. Well done. And now your son is 11 years old. Uh Marie, I have some questions uh in that direction. Is it okay for you to dive deeper into that story? Yeah, or would you rather move on?
Marie SchroederNo, I'm I'm happy to dive deeper. It's it's quite it's quite interesting, actually.
Christian SoschnerI'm I'm really a curious person. So uh when when I think back, so it's your son is now 11 years old, so it's nine years ago. And uh you said that your partner um or the father of the son uh kidnapped basically your son to Canada, and you realized that in Denmark and uh suddenly your son was gone. And uh I I mean I can imagine the first reaction is uh I do something horrible to that person and just fly over there and get uh get the kid back. Um how did you come to that point to to so no, let's resolve it in a different way, not uh prolong the hostility.
Christian SoschnerI mean, it would also be uh a chance to really start fighting with with each other and just uh truly extend that process over a few decades. And uh what what was your strategy to come to a different solution?
Marie SchroederYeah, so uh you're you're right, you know, that you know, violence and horribleness was maybe one on the list, but um just kidding, of course. Um but it was actually so it was speaking to um my my friend that I mentioned, and and very quickly speaking to to an attorney. So so actually getting the expert advice that, like, no, don't do that. That will make everything much worse if your goal is, you know, X, this is how you need to play it. This is this is the strategy we need to use. Um, and and so having that calm discussion with someone who is an expert that I I knew I could trust to do their absolute best using the legal frameworks that exist.
Marie SchroederUm, so I think it was that, I mean, that would that is the answer. So it was kind of getting input from somebody that I trust that knows how to solve this, you know, this major problem.
Christian SoschnerHow long did it take to solve it?
Marie SchroederSo there's uh there's actually um an act in international law called the Hague Convention for for child abduction, which and the goal of this is to many, many um nations are signed on to this. And the goal is basically to just immediately remedy this sort of problem. So where many, many of us know that in family court things can drag out for one, two, 10, 20 years, not 20, but you know, many. Um, the the Hague Convention basically just decides which country's court should actually solve the problem. And so this, I think within three months, I had my son back to Denmark.
Marie SchroederAnd then there was an appeal and et cetera, but that didn't really affect the the overall outcome. So it it is quite fast, actually. Um, so that that was obviously very important.
Christian SoschnerOut of curiosity, I mean my parents are divorced, but it was back in the 80s. So my mother uh wanted a divorce, and uh my father moved out and uh they were clearly separated. And back then the courts decided that uh one parent gets the kids and is responsible for the kids solidly. There was no co-parenting solution, one parent is out and the other one can move on, and it's the best of uh everybody back then in the 80s. Now I learned uh that today, in the uh in the 20s of this century, uh usually prefer a co-parenting solution. So even when something like your case happens uh and parents cannot get along very well, uh the court says no, uh it's the child's right to have uh contact with both parents, and both parents should find a solution.
Christian SoschnerBut after this event, I can imagine that you experienced with your partner, probably also on the other side, uh there might be some unresolved issues between the people. How did you resolve the situation? I mean, uh how how did you get in a situation where you say, okay, we can move on, we can move forward to do that.
Marie SchroederYeah, so I think uh just just to be totally frank, I think it's it's still not really resolved. So I I think it is absolutely true that um particularly in Denmark um and and many other countries, what you describe is exactly true that co-parenting is is the preferred solution and and sort of forced cooperation is is you know the way to go other than extreme situations, which apparently this does not count as, which is interesting. But um so so I mean, fundamentally it's still a problem that you know annoys me every every week or two.
Marie SchroederUm and yeah, I I think um this this may not be solved ever, really, but I think the way that I I manage it is um again by really trying to listen to my intuition. So when I make decisions um about my son's well-being, I really try and and tap into my own motivations for making a decision. Is it because I'm you know in a bad mood and want to like start an argument? Is it because I'm so afraid of looking like I'm starting an argument that I'm making, I'm being too accommodating? Or is it because I can honestly look in the mirror and think this decision is the best thing for my son, you know, given what I know today?
Marie SchroederAnd I really, really try and make decisions based on my own intuition as a mother, what is best for my child. Um, so that that's been a really, I mean, an evolving process. And of course, some days you look back and think, oh, maybe I could have made it, I could have done this a little better, I could have done it a little worse, I did great, whatever. But um, yeah, that that's the process I try to follow every day. And then the other um, the other coping mechanism that I've really been working on recently is is boundaries. So this is of course important in in both professional and and personal life, but um just again checking my gut and knowing what is okay for me and what dialogue, what contact, etc., is okay for me and what's not, and actually trusting and respecting my own personal boundaries.
Christian SoschnerSo you decided for a co-parenting solution then at the end of the day, today that is that was decided, yes.
Marie SchroederWell that happened.
Christian SoschnerIt was decided by court, by court. Uh I can imagine that uh many men and women uh are in a similar situation. I mean, it's the 20s and uh life moves on for many people. Um, what's your advice to parents who experience a similar episode? Um, what would you tell them to do?
Marie SchroederYeah, I mean um it's a really, really tough one. So I think, first of all, any any disputes, any disagreements that you can solve amicably through some sort of um therapy or you know, coaching or um mediation, that is always the better way to go if you can actually come to an agreement. And that's important. I mean, financially, of course, you you would like your money to go towards your child, not towards, you know, arguing about your child. So that's a really important factor. Um, also, I mean, children just want their parents to be happy and want to be loved and want everything to go smoothly.
Marie SchroederI mean, so they don't they don't want conflict and controversy around them. So anything you can do to sort of prioritize their, to maybe accept that, you know, this isn't what you dreamed of as a little girl and actually say, this is the reality, this is, you know, this is the situation that we're in for better, you know, with with pros and cons, um, accept that and and yeah, just just try to solve your problems through mediation, through, through discussion to the best and compromise to the best degree possible. That's of course where you start. Um yeah, and I think that's where my after that it's just sort of good luck and and hope for the best.
Marie SchroederBut but I think if you, I mean, if you can every single day kind of try to put your ego aside, look at your child, look in the mirror, and think, am I doing what I genuinely believe is best for them? That's, I mean, that's all you can do. And it makes you feel pretty good at the end of the day, actually. When you're really, really, you know, obviously you love your children and when you're really prioritizing them, that it it really does make you feel good. And you can see, I can see in my son how happy he is, how well he's doing in school and in sports. He's just a wonderful kid.
Marie SchroederAnd it's because he's, you know, deeply loved and he is, he knows he's he's prioritized and loved by both his parents.
Christian SoschnerYeah, the interesting thing is I think everybody thinks they do everything to the best interest of other people and themselves, and then at the end of the day, you end up suddenly in a conflict, and uh then you ask yourself, uh, how did I get there? And what I find interesting in these situations is I mean, uh ideally sitting down, talking through problems, finding a solution, finding a middle ground, finding a compromise, uh would be really best not only for kids but also for businesses. But sometimes it's really hard. I mean, people some people don't want to have boundaries, some people are afraid to set boundaries, some people are afraid to address something because they are not liked.
Christian SoschnerUm, did you find some strategies in your experience with uh with the father of your child and your child uh that help you in future um to resolve situations between people more amicably?
Marie SchroederI don't know how it's in in some in some ways, I think um absolutely. And um I think certainly sort of establishing and respecting my personal boundaries has been a journey for me and is something that I've um I'm still actively working on, and and that has been a major, major thing because when you when you sort of don't have boundaries and you don't, and there it you or you let people kind of walk over them, it's really hard to sort of stay calm, to be willing, to know what you're okay with compromising, to make deals, to make compromises that you're happy with, and to, you know, to not get upset and to not kind of perpetuate the argument.
Marie SchroederSo I think that's really in terms of my quality of life and state of mind and productivity, that has been an absolute game changer for me. Um, I think the other, the other really key piece of advice and my main thing is to not be conflict averse. So, I mean, nobody likes to take a fight, nobody likes a conflict, nobody wants to give people bad news. But the earlier you do it, it's just so much better. And I mean, yes, it's it's annoying, it's, you know, kilometer 29 of the or 39 of the marathon or whatever.
Marie SchroederIt's terrible. But then, you know, then it's done. And then you move on. And um, and then you can actually move forward with the team, with the the situation, with the foundation you want to have in place for for the next phase of, you know, whatever it is that you're that you're working on. Um, so I I think not being afraid of of conflict, but of course, respectful um and productive sort of discussion, not just sort of terrible arguing, but but manage conflict, I think, and and being able to sort of psych yourself up to take those difficult uh discussions um is just really, really important.
Christian SoschnerYeah, kilometer 39 at the marathon. Uh you learn, I mean, I learned around that point of a marathon how good your mind can become in trying to talk yourself out of something that you really love doing. And you say only two kilometers to go, but two kilometers can be really long. Uh, you mentioned setting boundaries, and this I think is a really interesting concept. Um, I mean, I have problems myself with that, and so sometimes then you say, Okay, you let people do something and say, Yeah, I like this person. And uh, when I say something, maybe the relationship changes, and then you hit a point, you walk over the boundary again and again and again, and you learn about yourself.
Christian SoschnerUh no, actually, I don't really like that, and I really hate that. And after a few years or a few months, uh, it can be too late, and all that comes out is not a friendly, please stop doing that. You shout at this person, and you mentioned that you became much, much better with this experience that you had in your life uh in setting boundaries. What early signals did you identify that help you understand this is something that you need to change and address early on and not wait a few years?
Marie SchroederYeah, again, being totally honest, it was um this is a very cathartic discussion for me. It's fun. Um, I think it's exactly what you described that I would sort of compromise, compromise, compromise, and then I would just out of, you know, just out of nowhere be totally burned out, have given too much, and then just be angry for, you know, in a disproportionate way to what you know, what the insult was. And I could tell that this was affecting um my my motherhood, for example, you know, my my parenting, and and it would upset, I I upset my my son on occasion, and he actually, yeah, and and so that that was kind of the main thing when this was sort of a pattern that I could see happening.
Marie SchroederIt was sort of like, okay, I just can't do this anymore. And I could, and once I sort of realized that this was an issue, you can sort of backtrack your own personality, like you can actually see how you feel, and you can see, okay, I'm starting to feel a lot of anxiety because this thing happened that was not okay with me. And I didn't, you know, I didn't sit stand up for myself, I didn't say anything, but that anxiety didn't go away. And then it sort of compounds and compounds. And when you sort of start checking in with yourself, checking in with your emotions and identifying what those triggers are, all of a sudden you realize, okay, if I just don't get in that situation, then all of a sudden all of that frustration, all of that negativity is gone.
Marie SchroederAnd so one, I can use that part of my mind for something productive. And two, I can just be happy all the time. And then if you know, if something that if something happens that I'm not okay with, then there's no discussion. There's no like inner turmoil as to what do I do to deal with the situation. It's no, this has to stop now, or I'm going to leave the room, or whatever it is. So it's just very, very easy to process how to make decisions in the future. And I mean, you have all this extra brain power and emotion and you sleep better and all that. And I think with um professionally, this it's the exact for me, it was basically the exact same thing.
Marie SchroederI I continually found myself in situations where I did all of this amazing work and I was working on 10, you know, not 10, but many, many projects at once. I was kind of above capacity. I was delivering all this great data or great, you know, insights or PowerPoint slides, let's be honest. Um, and then it would sort of I'd get some sort of you know negative feedback or some something would go a little wrong, something would slip through the cracks and it was like, oh, you know, that then the and the feedback wouldn't be, oh, it's so great you're working on 10 projects.
Marie SchroederIt's oh, you forgot this one minor thing and you know, now we're all up. And that just I got to the point where I was quite burnt out, and that was just so frustrating. And clearly it was there was it was the problem was was me because I saw that this happened and you know, on not just once, but like on several occasions. And and I had a lot of discussions with my with my um my mentor here at Novo. I've been working with a professional coach as well to actually deal with okay, how do I prioritize, how do I figure out what I need to be doing when, how do I set the boundaries?
Marie SchroederAnd and fundamentally, how do I tell my colleagues, no, I can't help you today because I have, I just can't deliver the quality that I want to. And again, I mean, it's all all the benefits that come on the personal side also come on the professional side. The quality of the work improves, the quality of your learnings, you know, the acceleration of your own expertise. It's it's all just um much, much better and also much more fun. And you can come to work much happier. And it's just a really, it's been a really great transformation in in my life, I think, in the last kind of year or so.
Christian SoschnerThere are a lot of uh great lessons in hardship, I think, uh to say in martial arts. Uh, when you walk through hell, keep walking, keep going. Don't stop.
Marie SchroederYeah, it's funny because we started discussing um this this podcast, and I started actually preparing, you know, what is the message I want to give? What do I want to talk about? And I sort of realized that this overcoming personal adversity to kind of also transform my professional career. This is maybe what I'm most proud of in my life. And I think, and it's not, I don't really talk about it very much, but it's not like some you know thing I need to keep secret. It's something terrible that I encountered and I, you know, succeeded in in overcoming. And I'm just so proud that I was able to do that and then actually learn from it, take take lessons, take the positives away, and just emerge as a much stronger, more confident, and and better person.
Christian SoschnerTotally agree. As a Viennese, I can recommend Viktor Frankly. I think it was he said who said uh that uh between uh stimulus and response, there is a little, you can create a space and you can decide what response you give when you're stimulated in a certain way. Victor Frankl is a uh concentration camp survivor and was a psychologist here in uh in Austria and Vienna. And uh you mentioned before, and I was thinking about Viktor Frankly when you said uh you're in this meeting, you have a presentation, uh, you spend a lot of time preparing that presentation, and then you have this one guy, the big boss, sitting there and just say, You forgot a comma on slide 55, and you say, God, he didn't get the message.
Christian SoschnerAnd uh you you realize you're getting upset and angry, and it would be so easy to shout at his face and say, Okay, don't you have anything else to say? I mean, this comma is not really important. Um, how do you handle a situation when you're in a presentation where you say, Okay, uh something goes wrong, but you don't want to hurt a relationship? It's better to take it out of the meeting and address it later. How do you create this space in yourself to decide very quickly what's worth addressing now and what has time until later without harming yourself?
Marie SchroederI it it's a great question. And um I'm I'm thinking back and laughing to myself. When I was doing my PhD in Oxford, I was working with my supervisor to write a review article and it was in circulation, which is a pretty high-impact um cardiovascular journal. And we were co-writing it with um a very well-known, um, very senior Oxford professor. And you know, he was super busy and yeah, he it was all very, very exciting for you know, 20-year-old me or 25-year-old me or whatever. Um, and we wrote him a draft, we we gave him the first draft, we were very excited about it.
Marie SchroederAnd then the next or a week later it came back, and one of the pages, there was a paragraph scribbled out and it said nonsense. And we were just like, okay, like this, and so our my first instinct, of course, was to be very upset. And to, it was exactly you know, the the boss picking out the comma on your slide and thinking, and just like, that's all you have to say is nonsense. Like, are you kidding me? We worked really hard on this. And we sort of, I actually I discussed this with my PhD supervisor um from Oxford, and and what we actually and I also came to the conclusion that okay, this guy is um really well known, extremely busy.
Marie SchroederHe's just notoriously busy, he's just doing this, all this amazing work. The fact that he is willing to take the time to co-write this article with us and to give us his input, that's a huge compliment already. That's a massive compliment. And the fact that, okay, he only has time to give the negative feedback, and that's that's what he's focused on, that means that the other, you know, every other paragraph in the paper that wasn't apparently wasn't nonsense, um, that those paragraphs were good. And that's the other way to look at it. And so I think that kind of thought process for me, it's it's also important to consider your audience, consider the collaborator, consider the person that's giving the feedback and understand that, yes, some people are very positive.
Marie SchroederI'm American, so of course I expect everybody to be super optimistic, super positive. Um, but some people, you know, some people are German and Austrian and are not, for example, or Danish, even worse, and not like that. And some people have different styles of giving feedback, some people have different styles of communicate, to communicate. And I think it's really, really important to meet people at the level they come from, understand their culture, understands how they work. And I mean, because again, if I'm giving that big presentation and the CSO of the company, the only thing he has to say is that I missed a comma.
Marie SchroederAnd does that mean that everything else in the presentation is is perfect and he agrees with? I mean, maybe, right? I mean, if if he's willing to put in the mental effort to notice that tiny thing, then he probably would have said something if he thought the whole hypothesis was just, you know, ridiculous. So I think I try and understand who people are and how they communicate before I then react to what they have to say or respond to how they have to say what they have to say.
Christian SoschnerDo you really think the Danish people are more unfriendly than the Viennese people?
Marie SchroederI don't know enough Viennese people to make a conclusive determination on that one, but they're definitely very direct, um, sort of Dutch style and their their directness, their their honesty. So, I mean, that's that's a good thing, right?
Christian SoschnerVienna is known for uh our unfriendliness. So we are with a high quality of life here in Vienna, but we are one of the most unfriendly people on this planet, according to statistics. So at least um, but I think this is really important to talk about it. I mean, uh, we can joke about it, but this experience is uh necessary to understand yourself and to understand uh uh other people better, especially when investing in companies. It can make so much difference when people know how to communicate with each other in a board meeting, and it can really be the difference, in my opinion, between success and failure.
Christian SoschnerWhen people go with the wrong communication style into a board meeting, uh you can really destroy the whole energy in the company in just five minutes.
Marie SchroederIt's completely true. And I just can't agree with you more in what you just said. I think that that having finding communication and speaking and listening to each other in a way that you understand and that enables the person you're speaking to to act in a positive way and to take feedback, you know, as necessary. It's just so, so important. And I think in when you're an investor, we work with um academics who you know come from one you know totally different environment than your seasoned Boston CEO of you know a publicly traded company.
Marie SchroederAnd we work with people everywhere in between. So being able and of all cultures, you know, et cetera. So actually having the the wherewithal or the awareness to actually understand who a person is and speak to them at level at a certain level, it's just a huge, a huge talent. And you can really see the people who are skilled in that area and and the people that that need need some work. Um, and actually, I I one of the topics for later in the discussion is diversity and and particularly gender in in um biotech and BC.
Marie SchroederAnd this is one area, um, maybe the most important area, where I actually think women are particularly good at sort of reading the room, reading the situation, and communicating to people at the correct level. Whereas um, yeah, I'll I'll just I'll leave it at that. But I I I have noticed that that communication styles amongst when women are involved tend to be a little bit more, maybe there's a little bit more listening, maybe there's a bit more kind of absorption of the topic and you know, and kindness and communication style. But again, that's a that's also a generalization.
Marie SchroederAnd I don't even have statistics to back that one up, just sort of anecdotal kind of experiences.
Christian SoschnerAs a man, you can put a lot of meaning in no words. Uh what's it, but uh it was, I think it was Jansen Huang in uh in a conversation with the Stripe CEO. Uh, this this uh this comma thing. So um the question was something like uh do you what must happen that you fire people? And Jansen Huang said he's the uh CEO of Nvidia and uh big success story in the last years, and he said, I don't fire people. And the stripe CEO looked at him, why? And he said, I torture them to greatness.
Christian SoschnerAs a ah, okay, it might not be a bad intention behind it when uh getting criticized. I mean, he was also interesting uh with in this conversation is that he said he has no one-on-one meetings, he does meetings with 60 people in the same room because he thinks everybody deserves to hear the stories and also to hear the failure stories, and he discusses failure, as he said, uh in this big meeting and not uh off topic. Um, what's your style uh in investing when you address with with boards?
Christian SoschnerUh I mean, fail must be addressed, you must fix them, you must fix problems. Uh, what style did you evolve?
Marie SchroederYeah, so I I actually can see um Jensen Wang's kind of point that you know, in taking the the big, I mean, in a way, it's it's like the military or something, right? Where if you torture everyone, then you kind of build camaraderie and kinship and this sort of it's the main thing to do. Yeah. So I I get that, but uh my approach is not that, um, surprisingly. Um so I think when dealing with, and again, this is um something I'm I'm learning and very much on a journey here as well, but when dealing with kind of giving and receiving negative feedback and communicating failures, communicating issues, I think it's it's very much best done one-to-one.
Marie SchroederSo preferably um in person, face to face, not not in writing, not you know, phone is uh maybe okay if necessary, but certainly in person is the best. And it should be done, I think, pretty quickly, not immediate. And I've obviously made this mistake where I've you know had negative feedback that I was, you know, in the moment and really annoyed about, and sort of spoke to a colleague when I was still in that mindset of not being calm. So everything I said before I didn't follow, and you know, I've given that that feedback before. But I think the best way to do it is to sort of again clear your mind, take a little break from it and the next sleep on it, and then the next day kind of communicate that issue, failure, challenge, whatever it is, one-to-one.
Marie SchroederAnd then hopefully you can make a decision together as to how to move forward. In the context of a board, if if a company is having it does have a negative result coming up, the way that we prefer to be told is again with the probably in a one-to-one meeting as soon as possible. Um, of course, if it's with the full board in an urgent meeting, that that's okay. But I think one-to-one, it gives everyone a chance to understand the problem, ask questions. And then in the board setting, you can um everyone is sort of briefed, they know what's going on, and then you can actually move towards decisions rather than just communicate.
Marie SchroederSo it can actually save a lot of time. Um, those the board meetings where you actually have everybody together and they have time in their calendar to devote to a certain issue is really important. So it and quite rare actually. So I I think the this pre-socialization of the issue and kind of making sure everyone is fully informed going into the decision is just the best way to use the time.
Christian SoschnerI totally agree. I totally agree. The uh board meeting, uh the best board meetings are when people already have uh agreed and decided on the topics and on the issues before the meeting, and the meeting itself is just to confirm what was decided before and not a discussion in the meeting. Um let's let's move on to the to the next part. Is there anything open in the first part about resilience, communication, and adversity that you would like to address?
Marie SchroederNo, I think that was quite an quite an interesting discussion. It was really it was really enjoyable.
Christian SoschnerI enjoyed it. My next part, the next part is your journey into venture capital. You started in academia, and it's not the most usual way, I would still say it in that way, uh, to move from academia, from an academic career into venture capital. Venture capital is still this niche area. What motivated you to leave academia and become a venture capitalist?
Marie SchroederYeah, so it was a stepwise process for sure. Um, and I think there are looking at our team, um, we're of course early stage investors. So there many of us have, not all, but many of us do have PhDs and maybe did some sort of postdoctoral work. But it is everybody sort of comes from a different path. And then of course, the more conventional um VCs where you you are doing more later stage product, it is again more rare, even more so. Um so for me, I think when when I was doing my PhD and started in academic research, it was um it was very much, I studied in Oxford and did some postdoctoral work in Toronto.
Marie SchroederAnd it was very much of the mindset that, you know, academics are the the true scientists. If you can't succeed in academia, then only then do you go to industry, you know, that kind of thing. So it was very, you know, pure academia mindset. Um and so I never really thought that I would want to leave because I, you know, I wanted to prove that I was the most successful and could do, even if I maybe wasn't the most suited to do lots of benchwork, which I think my colleagues would confirm now. Um it just seemed to be the way to go. And I never really thought of the other options and really thought of what else could be could be done.
Marie SchroederUm and I so I stayed in academia for a few, a number of years. And then um, when I was in Denmark, uh Nova Nordisc actually advertised their first cardiovascular research positions. Um, so they had a few years before seen the readouts of the LEDAR trial where Liraglotide showed not just um non-inferiority on CV outcomes. These were the days when, you know, the the uh DPB4 inhibitors, et cetera, were actually showed cardiovascular risk in diabetes. So now diabetic drugs, then uh diabetic drugs started having to show cardiovascular safety.
Marie SchroederLiraglutide not only showed safety, but actually protection in a power in a trial, not powered to show protection. So that was a huge result. And I think in in that context, um Novanordis decided, well, okay, if all our drugs need to run cardiovascular outcome trials, which take, you know, 10,000 patients over five years and are billion-dollar exercises, we might as well actually proactively try to make some cardiovascular drugs um while we're at it. And so around, I think it was 2018, they they started their their first preclinical cardiovascular research area.
Marie SchroederAnd um, they advertised the job. I was sort of um, I my fellowship in in Denmark, um, it was in Aarhus University, actually, it was ending. So I was applying, you know, for other fellowships, but also this came up and I thought, okay, might as well, you know, see if I can get this role. And um ultimately I decided I, my, my boss who hired me was I he was fantastic. It just seemed like a really exciting opportunity to start building up this new area of research. So you you had this sort of entrepreneurial kind of startup vibe in the context of a very wealthy and and big company.
Marie SchroederSo it had some benefits of both worlds. Um, so I just decided it was time to try something new. And of course, I really liked the idea of in academia, and many, many people had the same, even you know, great academics, career academics, have the same journey where they sort of think, okay, I've discovered all these amazing things, published all these great papers, but I actually want to transform that into somebody that affects something that affects patients' lives. I want to build a product. And I think that that mindset really appealed to me as well. So I thought, okay, I'll try, I'll try a little bit of time in pharma.
Marie SchroederUm, and so I spent five years at Novo Nordisk um in drug development. I learned an incredible amount from from my colleagues there. And I'm sure we'll we'll get into that in some of the next questions. Um, but one of the one of the things I learned was that um project management and internal drug discovery, that was, that was all great. But what really, what I was really, really passionate about was um external innovation. So it was, and and many of my colleagues told me the same thing that I was really at my best when um looking, you know, doing due diligence on external biotechs, working to integrate new products and ideas, working with academics to sort of establish um research collaborations.
Marie SchroederAnd it was just that was so much fun, and I got so much energy from that that at some point I decided, okay, when it was, you know, maybe I was ready for the next thing and I felt like I had learned what I was going to learn from the role I had. I thought, okay, I want to work in early innovation. Um, and quite coincidentally, um, no, the seed investments team at Nova Holdings was advertising a position that was sort of um suited for me. So I applied for that. I applied for a couple of other things as well and was lucky enough to get a role, a position here.
Marie SchroederSo I didn't really know um what I was getting into. It was um, and even even today, I think every day I approach um learning many, many things. Um, but it yeah, it was a really great move. And I've just I think coming into VC, um the so the first half of the of what we do, so the deal flow, the um doing due diligence, kind of under and then kind of understanding the deals we want. To make. For me, that's very easy because I can I've had enough scientific experience that I um I can look at a data package and say, this is interesting or this is not kind of, I can see the vision, I can see that part.
Marie SchroederAnd so that's a huge advantage that I have. But then when we get to the okay, let's send a term sheet, and then it's kind of like, okay, that all of this was totally new to me. Um kind of progressing the scientific check mark into the okay, well, is this a is the legal diligence, the corporate diligence, the IP, the financial, the finances all of this was is still something that I'm learning actively every day, again, with with the support of very skilled um co-workers. So yeah, that's that's kind of the journey and where I'm at now.
Marie SchroederBut it's been, it was just, I think the reason I made the move is just it's exciting, early innovation is exciting and it's exciting to start new things. And it's I think my mindset is fairly positive. I like to, I mean, of course, some things you don't want to work on, but many things you do want to work on. There are always gaps, but my mindset is more how do you fill those gaps rather than how do you kill something. So maybe that's why I'm suited to it.
Christian SoschnerYeah, you sound really excited and you smile a lot when you talk about it. Uh maybe, maybe it's a yeah, maybe it's your American spirit and uh for Viennese it's really uh overwhelming because we usually don't have that here. Life for Viennese people is always bad. So you have to come to Vienna and uh and enjoy the culture of the traditional Viennese uh coffee shop uh cafes, where with the old unfriendly waiters, they are not so much around anymore, but it was really uh a trademark from Vienna. Um before we move forward to investing in biotech, uh let's stay a little bit at your time at Novo, uh NovoNordisc and uh Nobo Holdings for the audience.
Christian SoschnerMaybe we can clarify the difference between Novo Holdings uh and NovoNordisk. Um, what's what's the commonality and what's the difference between these two topics?
Marie SchroederYeah, it's a great question. And this question is one that in every single call we're on, we have to explain. And I didn't know the difference until I left Novo Nordisk and came to Holdings. So it's a very uh very pertinent question. Um, so basically, the whole Novo group of companies, it all starts with the Novo Nordisk Foundation, um, which is um the a philanthropic, a philanthropic um evergreen foundation. It's one of the largest foundations, private foundations in the world. Um, I think it's the largest life science foundation in the world. Um, and they so invest their mission is basically to save people's lives and save the planet.
Marie SchroederSo they're they're fairly ambitious, I would say. Um, and but they um give grants mainly focused in the Nordic community to to academics, to sort of traditional um life science and planetary health research. And they're expanding more and more to do more strategic projects with the Gates Foundation, for example, um, with NVIDIA, um, Jensen Fuang came here a few a few months ago to plug in our new supercomputer. So that was very exciting. Um, so it's it's a very large uh private uh philanthropic foundation. So Nova Holdings is the investment arm of the foundation.
Marie SchroederSo the way that Nova Hold Nova, the the way the foundation gives grants is that basically they don't touch the principle of um their money and they rely on Nova Holdings to make sufficient returns and on our investments to sort of fund their annual grant giving activities. And so basically we're an investment company, we're a traditional VC with the foundation as our only LP. So um that's kind of the way to think of it. And we have investment teams ranging from, as I said before, from the seeds investment team where I am, where we create companies, we incubate things, um, we invest up through maybe series A kind of, um, but we do stick with companies through until exit.
Marie SchroederAnd we reserve maybe 25 million um dollars, euros on average per company. But of course, for the really exciting ones, we can go a bit higher than that. We also have teams that do more traditional venture investing, you know, series B, series C, that kind of thing. We have a planetary health team, an Asia team, a growth investments team, um, a principal investments team. They're the one who executed the Catalan steal, for example, that many of you may have may have heard of. Um, and we also have a capital investments team that invests in uh in sort of non-life science assets.
Marie SchroederSo that they do some what they do is a little bit different. Um, but yeah, so that's Novo Holdings. We're investors. And we, and actually, if you look at our portfolio companies, Novo Nordisk is the biggest of our portfolio companies. So we like to, you know, tell tell our colleagues that we we own Novo Nordisk. So that's very exciting. Um, but we um we have the a sort of um uh controlling uh stake in Novo Nordisk, also in Novo Nisys, which is a sort of enzyme um catalyst kind of company that's also quite quite large and publicly traded.
Marie SchroederUm and then we have you know a huge swath of of other, much smaller to larger companies as well. And then Novo Nordisk, um, I guess many of you know know this company. This is a traditional pharmaceutical company. They're they mostly develop drugs in diabetes and obesity. They also have some presence in some rare diseases, rare endocrine and rare blood diseases, um primarily, um also some cardiovascular, some liver disease kind of products and development. But this is a traditional pharmaceutical company, publicly traded, um, yeah, running developed, so ideation through development, sales, commercialization, et cetera.
Christian SoschnerA great European success story. We can be proud of it.
Marie SchroederYeah, I think the Danish, um, there's a number of Danish companies, Carlsberg and Mersk, for example, that have this model of a foundation owning the publicly traded company. And this um creates a lot of benefits because, of course, um, because we have a controlling share, Nova Nordis can't be acquired, you know, by by external parties. Um, but they do have the benefits of the public markets and public governance and all those sorts of things. So it's a really nice way to kind of run companies and it's had a lot of success in Denmark.
Christian SoschnerYeah, Nobonordisque was one of the few companies that uh skyrocketed while the the rest of the pharma industry went down after the pandemic. So and Nobonord disk uh went up. Uh but back to your journey. You started in uh had an academic career, then uh started working for Nobono Disc and then moved to Nova Holdings. So it was a stepwise process from uh academics to becoming a venture capitalist. When we look at your time at Nobel Nord Disc, what was your biggest learning?
Marie SchroederThere were so many. It's actually hard to um it's hard to answer in a short question, but I think I'll I'll I think I'll focus on two. So one is the just incredibly collaborative nature of drug discovery. Um every step along the way, if you think you're going to do something on your on your own, it's just just ridiculous. You you need to have these very large teams, even at the pre-clinical stage, you need a solid team of um of formulation people, technical people, chemists, biologists, etc.
Marie SchroederYou need that team around you to build a robust and reproducible um molecule, essentially, and to have the valid, the data package around it that you need to progress further. And then of course, when you get into clinical trials, it just the team size and the resource needs just spiral and they become immensely large. So I think the first thing is just having this huge appreciation for people that are different than you and figuring out how to work with people that you trust and take input to build something much greater than any of you could have built alone.
Marie SchroederSo that's learning number one. Um I think learning number two is how to assess the value, the commercial, the value to people or the commercial value, depending on how you look at it, of the science that you're doing. So I think when I came from academia, of course, as an academic, you want to know everything and you want to solve everything. And you know, knowledge for knowledge's sake is very valuable, which of course it is. Um, but when you're trying to build a drug, you actually need to understand why you're making this drug, who you're making this drug for, and what is the sort of unmet need that your drug can potentially address.
Marie SchroederAnd um basically that's what you know, the commercial, the market access, the pricing, all of those departments are formally there to kind of advise you on this. But already as a scientist, you kind of need to understand, yeah, who am I designing this drug for and what problem does it solve? So and that that was a really, really exciting exercise for me when I sort of started to get to work with the more with the sort of cross-value chain teams and kind of understand drug development from the more advanced commercial perspective as well as, you know, of course, from the bottom-up perspective.
Christian SoschnerYeah, great points, great points. I started working in life science in 2006 with a spin-out from Novartis, it was the Department of Rodgers Novak, and uh I became the one asking the uncomfortable questions about markets and who's it for unmet need, especially when it's uh spin-outs from universities here in Austria. Uh you mentioned diversity, working with diverse teams. I think, in my opinion, as a business person, it's really important to have a diverse team with a team with diverse perspectives and skills, but uh it's a little bit against human nature.
Christian SoschnerUh, people usually like to, I mean, I think they say uh birds of the same feather uh flock together or something like that in the United States. Um it's against human nature. So basically, working with a business person is sometimes hard with for scientists, they rather stay with academics. And also on the other side, uh business people rather stay with business people, it's so easy, everybody understands each other, we use the same code words and uh we don't have to explain it. How do you see the importance in biotech investment of diverse teams?
Christian SoschnerIs it important or uh is it really not important for biotech?
Marie SchroederIs it completely it's non-negotiable, it's so important that it's non-negotiable, and it might be the most important thing in building a biotech. So, of course, you need good foundational science, but you can have great science, and if you don't have the right team, it will fail. Um, you can have mediocre science and with a great team actually achieve something of value. So I would say um non-negotiable. And you're absolutely right that the diversity of mindset and understanding different people's perspectives and their role and the what they're bringing into the product that you're collaboratively trying to create, that that's I think the one of the defining characteristics of being a good drug developer or biotech, you know, um operator.
Marie SchroederI think if you're one of the, and and there's nothing, if you're an academic and you want to talk to other academics and stay at the university, there's nothing wrong with that. That's I think it's it's actually something for for people to look inside themselves and decide. If you're happy in academia, you are, you want to develop novel methodologies, discover new things, you know, work on knowledge for knowledge's sake. There's that's an absolutely fundamental part of society that is just is, I mean, it is the foundation for drug development, for technological innovation. It will be what saves the planet, you know, it's so important.
Marie SchroederUm, and that's that's okay. But then don't become a drug, if you're the kind of person that wants that to only work with people like you from that mindset, then don't become a drug developer. And and similarly, if you're um uh a finance person and you want to, you know, stick with I don't know what finance people do or talk about. I don't I don't really talk to them that often. But it but then you know don't don't start investing in biotech because if you don't have the scientific perspectives, if you if you don't know what's going on, and it I'm not saying that um, you know, an academic founder scientist should be an expert in in market access.
Marie SchroederThat's ridiculous. But they should welcome the opportunity, be humble enough to hear what they have to say and incorporate it into their day-to-day. For me, I think that um knowledge sharing is it's kind of what motivates me to get out of bed in the morning to learn something new from somebody else that's smart and passionate and excited. But yeah, you're right. I think to each his own, and the important thing is just knowing what kind of person you are.
Christian SoschnerThat's true. That's true. Charlie Manga said that it's really important to have um uh diverse skills yourself and also diverse teams. Um, when you look at biotech and at the management level, and we stay, you mentioned uh the mindset and the skills. When we stay at the skill level first, uh, what skills do you want to see in a team that is an so that it becomes an interest, interesting investment target for you?
Marie SchroederSo the skills in a team, um, so that's a that's quite a good question. So we um we are very comfortable investing in very early things, even concepts. So we um we want to see quality, but we don't, if a team is not fully formed, we're totally okay in bringing in the relevant people. And we have our um entrepreneur and residence network, we we have a big network where we of course can can support that. So I think um every case is a little bit different, but I think generally when we start working to build a team, we would like, and it's always a difficult question.
Marie SchroederSo, where do you start? You need enough money to build the team, but you need the team to attract funding. So every situation is a little bit different in how you execute on this. But I think generally speaking, we we want good foundational science. Um, so science that is is validated, so a drug target that's validated in in, you know, using human genetics and in patient material, that kind of thing. So we have a strong patient-derived evidence base for the science that we're working on. The the molecule that hope, I mean, sometimes there's not a molecule yet, but hopefully there is one.
Marie SchroederWe want to see um, you know, good uh kind of good parameters um and of whether it's a small molecule, oligo antibody, et cetera. Of course, what we look for is a little bit different. Um, but we want to see that for the stage that it's at, that it's sort of, you know, appropriately engineered and everything is looking good and on the right track. The screening strategy is good, the development strategy optimization, all that isn't manufacturing, of course. We want to see that there's some view to that. Um then I think in terms of the leadership, we of course want strong scientific operators with good knowledge of the target that they're working on and that the story they want to tell.
Marie SchroederBut we also really need to see someone that's okay fundraising, that's that's um has some business experience experiments that's experience that's okay going to tell their story to you know, annoying investors who'll ask stupid questions and be self-important and all these kind of things. So it's it's that kind of blend. Um, and but again, it's one of the companies I'm working with was um literally science, a target spun out of Harvard with the professor, and that that was it. And we started from there and are kind of in the process of adding in the drug development capacity, the um, you know, the the in this case, um, as board members, we're kind of leading some of the BD activities, but all the leadership, all the drug development, all the um some of the other scientific tools that we need.
Marie SchroederAnd that's okay too. Um, it's the more mature companies where you really want to see that most functions are are more or less addressed.
Christian SoschnerBut at the end of the day, it also means for scientific founders who are in the early stages that they should expect uh to become a team of uh people with diverse skill sets and uh not only core academics. And if someone wants to be a pure academic and only talk with academics, it's the best uh not to be part of the executive team at the end of the day.
Marie SchroederIs this a that's true, and that's exactly true. And I think um for you know a fantastic academic who wants the to stay in the academic environment, but also wants their discovery to impact people's lives, it doesn't mean they shouldn't start a company. They can absolutely found a company and serve as the founder, but then they shouldn't be on the uh the executive team. They should not take the CEO CSO role, they should serve as you know, founder, advisory board member, you know, and maybe get on a few in the initial fundraising stages.
Marie SchroederMaybe they need to tell the story a couple of times, but they don't need to be the one driving that process. And they certainly don't need to be the one driving drug development. In fact, many, many times it's much better if they're not, and they can sort of be free to focus on what they're great at on the academic discovery work, and and oftentimes that can be very supportive of the drug discovery, maybe not the critical path in making the product, but of course can be a great data package to show to um to venture capitalists or to pharma when when the time comes. So again, it's about figuring out what your vision is, what your goals are, and who you are, and then getting the right advice and team around you to kind of help help bridge those two things.
Christian SoschnerSo one part of diversity is uh the skills and mindset part. Um, the another part is the gender part. And I can imagine that there are many teams out there who say, okay, the five guys, we know each other since high school.
Marie SchroederYeah.
Christian SoschnerUh one graduated from Harvard, he's a lawyer now. The other one graduated from uh, let's say Stanford, he's uh top academic now. The next one graduated from Oxford, he went into business and was at this and that investment bank. So we have all the skills. And can you say, but guys, you're only guys, you need women on board. Uh, why does it make a difference when you have mixed teams? Uh, are mixed teams, in your opinion, better than pure female teams and pure male teams? Or is it absolutely nonsense and it doesn't matter at all?
Marie SchroederUm, I absolutely think it does matter. And actually, the team you just described is more diverse than many of the teams we see, which is like all Harvard people or whatever. Um yeah, but but I think, and and we sort of touched upon this before. I think gender diversity, um, uh diversity from you know where you come from from in thought, it's just really important. Because if you're a team and you know each other, you know how each other think, you know how you work, you're all aligned, you miss problems, you sort of um you of course bring a lot of bias into the projects and the programs you're proposing.
Marie SchroederUm and you don't necessarily have the same critical lens that somebody coming in from the outside would have. So there's also, you know, maybe you don't want to offend your friend. Maybe you don't want to, you know, tell your friend that what they're doing is nonsense and actually make what you're doing better. Um, and then I think the the way I think it's just when you have people from different um genders, different ethnicities, different walks of life, you can just communicate in a more effective way that um, and and of course, when you're building a company, you need to communicate to many different stakeholders.
Marie SchroederSo there's there's your own employees, there's your board, there's BD conversations, there's, you know, if you want to collaborate with some scientists or whatever it is, and you need different voices to communicate to the different types of people. And if you think you can just, you know, shout and send emails and it all works, it doesn't. It absolutely doesn't. You actually need to be on to consider where the person you're speaking to, where they're coming from, what motivates them. And so having more brains in the room that can that can kind of consider different people's motivations and you know, triggers and et cetera differently, you're going to have more effective communication.
Marie SchroederSo there's also, I mean, of course, uh, one of the big elephants in the in the biotech room, women's health issues, which of course is a massive untapped market. Um, we're half the population and there are things like endometriosis that are extremely common that there's no therapies for. And I mean, you talk to any VC and they will say women's health is, you know, other than Melinda Gates, fortunately. But um any VC will say, you know, you can't invest in women's health. There's no market, it's just, it's just a disaster. There's no research, no good science, et cetera. So again, I have to imagine that the more women come into Biotech and VC, the more that these sort of underserved women's problems will be addressed.
Marie SchroederAnd that's not just good for women, that's actually good for investors because, again, the market is going to be massive. I mean, women actually seek healthcare and you know, are again, many of us. So I think that there's just many, many reasons to consider um for an individual company, but also for the field in general. How the more need, how the more people you have in the room, the more needs are considered, the more problems are addressed, etc.
Christian SoschnerYeah, I totally agree. I think this is the key point for diverse teams and the key argument, you see more problems. Uh you just have uh uh a wider perspective.
Marie SchroederYeah, exactly. Exactly.
Christian SoschnerI mean it's not only uh gender, it's not only mindset and skill, it's also ethnicity, uh, social background. Um people just see different problems. And uh especially when you think about uh rich people have other problems than poor people. And you they can benefit from both sides because you have the rich perspective, you have the poor perspective, and especially in a company. I mean, when a company drifts into crisis and comes close to bankrupt, which usually happens with startups, uh it might be really beneficial to navigate these waters when you understand how it is to work without money and to keep things moving forward without having anything on that.
Christian SoschnerUm how do you see social, social backgrounds? How do you see ethnicity in in the startup world? How important is that for you?
Marie SchroederYeah, I mean, again, I think generally speaking, the more diverse a team and the more, I mean, when you look at the sort of who we are on a company's webpage and you see that people don't all look the same, it's just really encouraging. It actually seems like the team has considered who we want. It sort of seems like instead of just opportunistically grabbing the people around you, people the company is actually considered who is the right person for this role, who brings something unique and different into the company. And so I really, really respect that. And I think um, again, you you spoke to being able to operate in different ways, recognize different problems.
Marie SchroederMaybe if you need to unwind or deal with adversity, different perspectives, of course, help. I think also another major, major issue in obesity therapeutics, for example, is um distribution through the um the less developed world. So, I mean, basically, US and Denmark can get our obesity drugs, and nobody else really um. So, how do we actually, and that's, I mean, if you can bring a lower priced, more shelf-stable, more easily produced product that that covers much more of the world. I mean, that's even if the price is low, that's going to be a huge market and a huge commercial opportunity.
Marie SchroederSo I think not just being focused on, okay, let's develop gene therapies for a niche population in Boston, but consider how do we bring new therapeutics and new medical care into India, to China, et cetera. It's just really important. And actually, back in Nova Holdings has we have offices in China and Singapore, and we're built, we're making an office in India as well, exactly to address because exactly to address those those challenges is that you know the healthcare landscape is very, very different in different countries where cultures are so different.
Marie SchroederUm, the the healthcare kind of system is so different. And so we can address that both, you know, to very much help people and elevate people's healthcare and standard of living across the world, um, improve planetary health across the world, but also reach a massive market that can help our bottom line.
Christian SoschnerBefore we move forward to the future of healthcare and investing in biotech, let me ask you one final question the diversity. And I know after this question, probably many VCs will hate me. And my fundraising career is over in the industry, but let me ask you this. Um, when we look at the venture world in the Western world, in the United States and in Europe these days, especially women in VC, how diverse is venture capital in 2025, really?
Marie SchroederIt's actually, I think it's not as bad as biotech. So biotech is very is 90% male. I mean, really bad.
Christian SoschnerBiotech is 90% male?
Marie SchroederMaybe 80%, but I mean if you look at C-suite leadership positions in biotech, it's very bad. I think VC is actually getting better. And and particularly in European VC, there's quite a lot of, you know, um, if you look at uh Sofanova, Jado, Novo, uh Forbian, et cetera, there's quite a lot of really, really successful, well-respected kind of female partners that are leading the way in inventor, also in, of course, diversity and that kind of thing. So it's I and if you again look at the um the sort of analyst associate level, there's I I think there is a real effort to at least uh to interview equal numbers of people for roles.
Marie SchroederAnd of course, that's that's helping um from the bottom up. So I think this is actually VC is not it's not great, but it's not terrible, but it it's the biotech side that's really, really bad.
Christian SoschnerI always thought uh it's the other way around, that more in the finance part. Um uh it's good to hear that I was wrong.
Marie SchroederUm and that's biotech. Of course, other industries I can't speak to.
Christian SoschnerYeah, yeah, no, no, no. But I've always thought that that um there are more women in biotech because it's uh basically uh you said women you should have more social skills than men, and uh uh helping uh profession uh might be more appealing to women. And so I've always thought uh there should be more women in biotech than men, actually, and disinvesting and turning things down and saying no and being sometimes rude and crushing dreams. Mark Andrew Anderson said this in a podcast our job is to crush dreams, and we do that. That's the male thing to do. But actually, you said it's the other way around that there are more men in biotech in the at the sea suit level, and uh it's getting better in the venture world.
Marie SchroederThat that's been my experience so far. Yes.
Christian SoschnerThat's that's good to hear. That's good to hear. Let's move uh forward in the conversation to investing in biotech. Um, early stage investing. I learned in 2006 early stage investing can have a lot of meanings to different people and many different meanings. Uh, what's early stage investing for you?
Marie SchroederYeah, it again has many different meanings and can be many different things. Um, so for us, so just to give you an idea, um, two of the deals that I've worked on this year. One is, as I mentioned, a spin-out of a target from Harvard with a professor, and we basically the employees of the company are this professor as a um as a consultant, and we have one of our venture partners as a day and a half a week, and then we have you know some consultants and an SRA and that kind of thing. So very, very small company creation. Um we put two million dollars two million dollars into that company.
Marie SchroederSo very, very small. Um, I'm working on another deal that's a sort of series that actually um I can give you two examples. So another deal that one that was announced today, actually, from from um our team was investment in a Swedish company called Anacardio. And this was quite a small round, but the company is has just completed a phase one B. They um they had an extension round to to complete the phase two A, and then we'll be looking at kind of a phase two B after that. So that's actually fairly the sort of side entry post-Series A is is, you know, maybe not so early, but that that still falls under our remit.
Marie SchroederAnd so the sort of series A type, um larger series A type investment is still in scope for us and and everything in between. So it's really, really case by case for us. So do we see some, uh, do we have a concept we like where we want to fully build a new company? Do we see, you know, a couple of publications from some scientists that we want to spin out and build the company around the science? Do we, or do we have um the series A companies, of course, have a CO, CFO, you know, pretty well-formed C-suite, lots of data, entering clinic, et cetera?
Marie SchroederSo it's it's a range for sure. Okay.
Christian SoschnerMy next question to you is um I mean, everybody wants to bring value these days to other people. And um reaching out to investors always mean taking some of the time out of the budget, of the time budget. Um, what's the minimum requirement you want to see in the pitch deck? Let's assume a cold email. What's the minimum requirement that you want to see in the pitch deck that you say it makes sense to send it to you?
Marie SchroederI think it's it's a good question. And we are definitely more receptive to um uh not perfectly honed pitch decks than many other funds are. So I will say that if you have great science, if you have a couple of nature papers and an idea sent and it's not in a deck, that also works. Um it's I I think generally speaking, we'd like to know what the problem is that you're trying to solve. So, what is the indication? What are you thinking of? Um, what is your strategy for moving forward? Is it a, are you, you know, are you working with some medicinal chemists?
Marie SchroederDo you have like what stage is the chemistry at, et cetera? So give a good, whatever you have, give a good and clear introduction as to where you are. Um and any any sort of human data is really important. So it would be great if you have, you know, taken some some tissue biopsies and can can show the efficacy of your concept in those or some human genetics work, et cetera. Um yeah, and where you want to go and what you're asking for, essentially. So you want how much money to get you where and and what is what is the plan to get there.
Marie SchroederSo I think that's kind of what we want to see. But if that is an email and you know, three nature papers and just like a I want to talk to you about this, that's fine. And one um for our team, it's extremely common. So this the deal, the Anacardio deal I just mentioned, the Swedish company, um, we've been looking at that company for about three years, and it was never the right time until until it was. So um just because you you send us something that's not polished and not finished, and it's not the right time for us to invest now, we have ample precedent that it could be in in the future if you keep developing.
Marie SchroederAnd we're always happy to say, okay, you need to focus on this, you need to focus on this, call us at this time with this data. So I would say, yeah, I would say I would way rather have somebody send an unpolished, unfinished concept than spend, you know, as you say, it's a huge time suck to make a pitch deck than to spend, you know, half their life making a sort of body pitch deck without kind of the right inputs. And so just and be open.
Marie SchroederI think being open and honest is really important. If you don't know how to make a company, but you think you have a great idea, then tell us that. And then I mean, we're company creators, we can help you. And it's it's actually a lot better for us to help create something new than to take a company that was founded maybe with a messy cap table, some investments from you know, people that we don't that aren't professional investors and a company that was founded messily. Um, it's much harder to work with that than to take the raw material and to create something ourselves.
Christian SoschnerBut there are three questions I would like to ask you. Um, the first one is I interpret you in the way in a way that uh in your opinion, it's better to go out with an unpolished idea in a rough pitch deck, or for example, a draft on a napkin shoot a photo and send it to ABC or to you, rather than spending three years polishing an idea that might not find the market. Um Is it really so that uh people can approach you with unpolished decks, not spending uh years uh working on the pitch deck, putting together the perfect team, but just testing the idea with you, you give input, and then you still are interested to continue the dialogue later on.
Marie SchroederThat's absolutely true. Um, and that that's true for our fund. For other funds, of course, that's not true. So I'm I'm speaking specifically as a um a seed investor company creator kind of perspective. And I I um from what I understand, many other um company creators would also come with raw material, if would would rather be approached with raw material to create the company they want rather than sort of invest in somebody else's company. So I think it's really about knowing your investor and knowing what makes sense um or not.
Marie SchroederAnd I think yeah, I it's really I think what what I'm always happy to sort of field questions. And if somebody wants input, and I mean maybe the answer, and I'm not saying the answer is always um, this is great, we'll invest tomorrow. It's rarely that, but we're always happy to give input and to help put you on the right path and give you suggestions. And I think it's just um for people, uh, I think getting the for people that don't have aren't seasoned company creators, aren't seasoned entrepreneurs, it's always better to get input than to sort of waste time trying to do something that you're not an expert at.
Marie SchroederGet get the expert input and and work from there and take it step by step. It's also about humility, though. I mean, that that situation you have, I mean, it it requires somebody coming to you saying, This is what I have, you know, I'd like your advice. I don't know what the next step is. So it's also the mindset of being willing to collaborate, being willing to take somebody's feedback on board and to build up, you know, eventually a team. It does take that mindset for sure. But yeah, if you're going to sort of um, I mean, many other funds that that do, I mean, our ventures team, for example, they I mean, they invest in in sort of maybe I and D stage, but usually companies with some clinical data.
Marie SchroederSo obviously you need a pitch deck and a leadership team if you're going to ask for an investment from them. So it is being mindful of who you're sending the deck to or the kind of idea to.
Christian SoschnerAbsolutely. But you are the person uh people can go to to ask early ideas. It's good to know because it's really it's really a huge question for first-time founders. They usually don't have any experience. And they very often ask uh, when is the right time to approach an investor? And when I get a no, does it mean forever? Or is there another another way? Uh you said uh you looked at an asset for three years and it was never the right time. Can you tell a little bit more about the story behind that? Why it took three years and why you still were open after the initial meeting to continue engaging with the team and not just uh come to a final no and say, well, you contacted us, you send us one pitch deck, it was a no, but you extended it for three years and then said that you invest.
Marie SchroederYeah, so and and this um again, if you if you look at the Nova Holdings LinkedIn page or whatever, um, there's a press release about the company Anacardio. Um it's a Swedish company and heart, a single asset company in heart failure that's starting a phase two trial um now. And actually, my my um our our board member will be my my colleague Jarn Peterson, who's a senior partner in our team. And so he first saw, I think it was about three years ago. I hadn't actually joined No Holdings yet, so I didn't see the deck at that point. But this company, um, it was the founder is a uh Swedish cardiologist called Lars Lund, who's very well respected in the heart failure community.
Marie SchroederHe's at the Karolinska, um really top-notch academic. Um, he had some academic work that was very supportive, um, so human academic clinical work, very supportive of this one particular um target as a sort of a therapy for end stage heart failure. And he really believed in this target and was very excited about it. Um, and he he created this company. They the company in license they found some chemical matter from another pharma company in licensed at chemical matter and were able to start a phase one trial.
Marie SchroederWhen I looked at the asset first, it was right when I started, so so about not quite two years ago. And at this time, we were excited about the animal data. Um, it looked good. The initial phase one data looked interesting. There was a lot of pros there, but there was definitely some risk associated with the molecule as well. So it, I mean, there was no efficacy data. There was the the phase one was very small, the um not really enough to show safety. And if you know anything about the heart failure investment space, um, therapies for end-stage heart failure, I mean, there aren't really any, and um therapies that make your heart beat kind of better.
Marie SchroederUm, there's actually quite a lot of risk in the community around that type of therapy because there were there were some drugs that actually came to market uh 10, 20 years ago that ended up causing more and more, even though they made people feel better, they cause mortality. So they were taken off the market very quickly, and that was a bit scandalous. And this class of drugs kind of has a bad name. So there was some risk associated with the molecules that we just weren't ready to take on at the stage before there were clinical data to kind of clear that risk. And so when they sort of were able to complete their um the initial or the phase one B trial, I guess, where they were in heart failure patients and did follow the patients in a multiple dosing paradigm over seven days, and the TOX data looked quite good, um, quite, quite encouraging.
Marie SchroederThen it was all of a sudden that big risk that we had flagged that we just weren't willing to take, that that had got, I mean, not gone, but it had been substantially de-risked. And so at that time, we we thought, okay, well, actually the biggest risk um we're we're kind of happy taking on. And there's multiple, there's again, um, there's quite a nice path. So the investment we did now is a bridging investment to a larger round. So we will have another chance. It is sort of like a built-in tranching system where we'll have another data readout where we should actually see some efficacy data.
Marie SchroederIf that looks, if that looks good, then we think that's a profound de-risking for the phase 2B trial, which is, you know, hundreds of patients fairly expensive. But putting that money in when you've already seen that the drug to some degree seems safe and works in in a small population. I mean, that's that's the investment that we really, really like. So again, it's about um sort of a good track record, good founding team, um, good foundational data. And the time there was maybe a little bit too much risk for us at that time.
Marie SchroederBut then, you know, once that risk was sort of managed, then of course we wanted to invest in in that particular company. And I think this is very common for earlier stage companies as well. So if somebody comes to us with a sort of hit-to-lead stage um medicinal chemistry compound, you know, with one or two assets in the pipeline, maybe we don't want to put $20 million into, you know, an a med chem campaign that could go, you know, in a million different directions. Maybe that's not the sort of risk, that's not the investment we want to make.
Marie SchroederBut all of a sudden, when you are approaching, you know, you have your your eyes on a development candidate, and then all of a sudden the risk profile is very, very different. And maybe that's the investment we want to make. So, and again, I know it's really frustrating for founders that when you really need the money, nobody wants to give it to you. And then when you sort of have a pretty good case, then all of a sudden it's it's easier to find. But yeah, that that is unfortunately the way the way it is for us. And it's about finding um the right uh the right uh investors or the right funding bodies that do take that do take on much earlier risk.
Marie SchroederSo yeah.
Christian SoschnerYeah, it's it's I think it's a good lesson for founders. Um, a no from a VC doesn't necessarily mean it's a final no. Uh it makes sense to stay in touch, to keep updating, to keep uh not turning around at the conference when you see them, because they said no two years ago, which could mean uh it's no forever. So there might be a later point in the development where the asset becomes hot and interesting again.
Marie SchroederYeah, and actually just today um I received a Christmas card from a company that I looked at last year. And my feedback then was, you know, this is interesting, but we'd like to see some in vivo proof of concept data. And I just got a Christmas card today that was we have really exciting data to share. We'll follow up later in the quarter, you know, happy new year. And it was like, oh, I that was such a nice touch. It was like, wow, this is, you know, I've I've that has not happened to me before. And it was just really great. So now they're certainly back on the radar. I'll probably reach out, you know, maybe after JPM after all that chaos settles down and just see where they're at and see what that data does look like.
Marie SchroederBut by all means, if you're a company, you're working in the right direction, you continue to address risks in a sort of um regimented and um sensible way, then by all means, when you do have have data that kind of boosts the value and de-risk your company, go back to investors. And I don't think that's just for us. I think that's for for many, many investors. A no now doesn't mean that a you know an updated data package that that does take out a lot of the risks that were you know flagged by the investor up front.
Marie SchroederBy all means, go back with that data.
Christian SoschnerSo the learning for the founders then is uh, in my opinion, that uh getting funding from a VC is a process that uh usually takes a longer time. And the first meeting is just the first meeting of a series of meetings. It's not the final no, it's not a final decision after 30 minutes, it's just the starting point.
Marie SchroederYeah, yeah. And I mean, of course, there are situations where you could get a final no. I mean, if something is strategically out of scope, or I mean, of course that happens. But I think um and I think you need to be ready to tell a story and you need to sort of set the expectations for the meeting appropriately. So don't pretend you have that you're in clinic next year when you don't you have you know some hits in a med campaign. So be realistic and and kind of very address the gaps and have a plan to move forward. But yeah, I I think by I think it's quite rare for any of the funds I know where a no means final no, always come back with new exciting data.
Christian SoschnerOf course, and always given that it's the right strategy, it fits the fund and it's the right point in time. Uh when someone pitching uh, let's say the latest med tech to you probably doesn't make sense when you don't have it on your strategy. Um, but then if no medical parents uh you mentioned that you uh did uh do your investments uh stepwise before uh with this three-year story. Uh, I like the term that um uh Alex Savonkov uh coined on my podcast molecular dottery, he said in the podcast two years ago.
Christian SoschnerHe runs in silico medicine. Um, how do you approach investing in biotech when we look at the risk perspective? I mean, a molecule out of uh lead optimization has, I think, 1% chance of success. How do you manage that in your fund?
Marie SchroederYeah, I mean, for one, we accept that. So we don't pretend that you know, that everything is going to be successful. So I think having the right mindset um is the first, the first thing to do. Um, and then it's really about building a good plan. So what so what is so it's identifying with the molecule in lead up, what is the key risk um at that stage, and what is the next key value inflection point? And how do you get to that point in the most lean way? So it's it's all about balancing.
Marie SchroederI mean, if you drip feed a company, it's probably not going to be successful. You need enough money to capitalize the company that they they they have a few shots on goal, they have a few chances, and they can invest, they can actually put the resources in that that are needed. But at the same time, you do need to be somewhat realistic that about okay, this is where I'm trying to go. It will take this amount of money approximately in this amount of time, and this is what I'm going to deliver at that time. So it's about it's developing this mindset of understanding what's on critical path, what is absolutely need to have to progress to the next age of your molecule, what is also nice to have if you have some extra cash floating around.
Marie SchroederUm, and that's kind of the mindset that we take into all of our investments. And um, it doesn't just mean that, okay, we're all putting all the money into Medchem and that's it. Of course, um, very critical. You sort of do want to plan for success. So, of course, you also want to understand, okay, what is the manufacturing route? You know, what do we need to do to get to our ID enabling studies? What are the species? Do we need specific assays to build? What is our translational strategy? Do we have, you know, relevant biomarker? So it's understanding how kind of what makes sense at what time so that you can kind of go efficiently towards towards the clinic and towards the next points, but also not put in more than you need.
Marie SchroederSo it's a bit of an art and it's it's certainly a dialogue. So it's great when a company comes to us and says, this is our plan, you know, do you want to invest yes or no? But usually we'll say maybe, but you know, we need to get rid of this white space. And don't you think we need some translational work? And do we really need this mechanism of action stuff, or can we post So it becomes a dialogue where us and syndication partners, of course, need to be comfortable with that the capital you put in is the right amount for the risk stage that you're at.
Christian SoschnerExpect a dialogue at the end of the day with the investor and not a monologue.
Marie SchroederDefinitely for us. I I can't even imagine. It's like the idea of having, you know, just say us saying yes, go. I mean, that's just ridiculous. That would never happen.
Christian SoschnerWhen when when I read through your preparation material that you sent over, uh, I found a term that uh it's the first time that I heard it. So maybe we can uh dig a little bit into that. You said that uh you described venture capital as a self-fulfilling prophecy. What do you mean with that?
Marie SchroederSo I think um, and and again, this is a bit of a generalization, but I think, I mean, as um Novo is is obviously one of the leading investors, um I think we have this. So I guess I mean two things by it. So one, we have the skill sets on board where if you um come to us with your early stage company, we have a very, very good chance of if we decide to put in money and personnel and resources into building this company, there's a pretty good chance that we'll at least set it on the right track for success. So um if you take, you know, two founding teams with similar assets, similar stage, and an investor like a Forbian or Innovo or, you know, these really experienced people come in and one company is assisted and one is not, of course, the company with these professional kind of company builders on board will do better.
Marie SchroederSo that's that's one sense is that the quality of the company becomes better. But I think um the other part that of course we we all know is true is that investors have this huge, you know, psychological thing where if somebody like Forbian is investing in a company, then it's like, oh, that must be good, you know. So they they must have seen something exciting if that guy thinks it's a good company. And so there is this, it's it's just so yeah. So I think there we also have this psychological mindset where if if we have, there's a lot of other investors that we work with a lot that we trust that we know well.
Marie SchroederAnd if they're bringing us an opportunity to sort of potentially invest in, then we're just much more open to it than just a cold call or a cold email. So I think that psychological factor of, okay, we know Novo built this company, so there's going to be some quality. They think it's good, so they they have good judgment. So therefore, we'll look, you know, we won't just look what once at it and pass, we're going to look at this really, really hard because it's probably of a certain quality there's just assumptions made about the company, I think, that that in many cases are true. It is based on, you know, kind of the the real experiences of seeing Novo built companies and seeing that they are done with quality.
Christian SoschnerYeah, so there is some hurt mentality in venture capital.
Marie SchroederYeah, of course. We we all all investors have this big FOMO kind of thing. So it's it's totally it's it's just the way it is.
Christian SoschnerReally, it exists before.
Marie SchroederI would say it does. I would say it does.
Christian SoschnerSo is a for did you hear Forbion you've seen? So why are we not? Maybe we missed out something.
Marie SchroederWell, I think when when um and and we uh we work with the guys at with the the team at Forbian all the time.
Christian SoschnerJust choking, just joking.
Marie SchroederNo, but but it's we really, really like them. But it is absolutely true that if if they're doing some sort of interesting that we definitely are are very interested to know what they're doing and what they think and what they see because we definitely trust them and we trust them to spot interesting opportunities moving forward. And it's great to get their input. And that's one of the fun things about syndicating with with other funds and getting other minds on board is to just hear their thought process because, of course, they'll prioritize different things, they'll be excited about different things, they'll you know want to fix and they'll spot different problems. So, yeah, there's definitely that that mentality, I think.
Christian SoschnerYeah, yeah, I think I mean every fund is a trademark. So Wellington Partners, Sevencha, uh Zeroba, for example, also in Ireland. I mean, these are guys and people and women um who spent a few decades uh together, a few centuries on uh investigating and finding the next big thing. Uh, but what about the contrarian approach? I mean, when you want to make a 10 to 100x, wouldn't it be better to go in the other direction and say, okay, where is nobody looking yet?
Marie SchroederI think that's also true. And I think we feel as as sort of company creators, we do feel like we have this sort of superpower, or you know, that's a that's a bit flip, but um, we do feel like we are empowered to take things that other other investors may just see, you know, this is too early, come back in a year. We can actually see those opportunities and help build them and advance them and put them on the right path. So I think that is another huge element of what we do is we do like to spot these, you know, the future of medicine, what is the next big opportunity, um, that kind of thing.
Marie SchroederSo that that is also fun.
Christian SoschnerLet's move to the last part in the conversation. I hope do you have some a few minutes left?
Marie SchroederA few minutes. I I need to get my son at school and not too long, but yes, I do have a few minutes.
Christian SoschnerThen five minutes probably. Uh, when we look at the future of healthcare, um, when they read through the internet, there are a lot of conspiracy theories, farmer needs patients, so that's why a farmer wants everybody sick, uh, which in my opinion is not true. Uh, where do you see, I mean, when we look at health generally, where do you see the future for pharma?
Marie SchroederYeah, I I think the I mean, I I also Pat, especially from my experiences with Nova Nordisk, and and um that's that's my main experience, they certainly don't want people to be sick. It's a very ethically minded company, and the scientists and the people working there are truly committed to to making patients feel better and developing new therapies for them. And the sort of, I mean, it is just sort of a fact of life that many people unfortunately will be sick in their life and there will be health problems. And I mean, the more you treat some health problems that you're you'll you're you're postponing to a new generation.
Marie SchroederSo I I don't I think pharma and novonordisk absolutely invests in healthcare infrastructure, in um in lifestyle kind of modification programs, et cetera. They absolutely do invest in that, and that by no means will you know limit their market. If anything, it'll help their brand and kind of help the overall product, I think. Um, but I do think that in so in pharma, I think there's sort of two parallel directions that need to be addressed. So, one, of course, is what we're all excited about the advanced medicinal products, you know, the stem cells and the regenerative medicines and gene therapies and and cures for these really, really severe diseases.
Marie SchroederAnd those, you know, are advancing, will continue to advance, and is a big part of what we do in venture capital is investing in these companies with the future of medical products. But I think the other the other path is um is actually making drugs more affordable and more and disseminating them to more to broader areas in the world. And if you talk to the novonordisk um obesity strategy people, for example, they of course want you know uh new therapies that are better than what exists, but they also want therapies that are more democratized, that where patients have to dose either less frequently or they can take a tablet that's much cheaper.
Marie SchroederIt doesn't necessarily have to be about hitting 25, 30% weight loss. It can also be about hitting 10% weight loss. But in many, many people, it can be more of a preventative therapy, it can reach a wider population. So I think by all means, there's there's eyes in both directions. So, you know, the fancy therapies that are that will, you know, cure disease, but also making therapies more accessible. Um, I think that there will eventually, I mean, this the anti-aging and health span and all these people um that that are investing in these areas, maybe we're not ready for health span and and life prolonging drugs yet.
Marie SchroederAnd the regulatory past not clear how these drugs will actually be approved is uh mind-boggling to me still overall. But I think that that ultimately, I mean, we know the market is there, right? In some ways, it's very much like obesity, that you know the market is there, but how you reach it is just yet to be determined. I think absolutely that that will come in the next, you know, 10 years, something like that, where we will see more, not just billionaires investing in what and who knows what, but actually concrete assets that are being progressed through the clinic in a reasonable way.
Marie SchroederAnd maybe this is taking indications like sarcpenia, frailty, some neurodegenerative conditions that are associated with aging. That's obviously the place to start before you go for the broader population. Um, I mean, GLP1s and some of the obesity medications might go this route as well eventually. Um, but I think there there will be more, uh, there will be pharma companies and biotechs that are looking more and more in that direction in a real and achievable way. Um, and I think preventative medicine, um, I'm I'm kind of hoping will become more and more kind of commercializable, if you will.
Marie SchroederIt's obviously a very difficult place to enter the clinical trials. Um, if if this if the sort of regulatory paths stay what they are now, the clinical trials are a lot more difficult unless you're looking in rare genetic diseases or or that kind of thing. It's more difficult. But obviously the financial, the socioeconomic benefits would be massive if you can actually crack that one. And I know many, many pharmaceutical companies are working in that area very, very actively. So that's an exciting place as well.
Christian SoschnerYeah, amazing times, amazing times for farm and health in general. I mean, all these uh new gadget that we have data, uh, connectivity, uh, supercomputers, quantum computing, um, it will be very helpful. And especially also the billionaires that are now in their uh early 50s or early 60s, afraid of death, not the need to invest in health. And this will also drive the market forward. Uh, in the last uh one or two minutes, is there anything open from this podcast that you would like to address at the end?
Marie SchroederI don't I don't think so. I think it was a great discussion. I don't think there are any sort of real outstanding points. Uh, your your point about quantum healthcare, that is also something that the Nova Nordists Foundation as well as Nova Holdings are actively in um addressing as well. So we're starting to look into quantum technologies to invest in. And that's obviously for my my 11-year-old son. Um, I think I'm he he loves gaming as you know, as many 11-year-old boys do. I definitely want him to, you know, explore what quantum computing is. It's one of these areas where I can't really tell him because I don't really understand, but um I think he is at the right, has the right sort of brain plasticity and openness to learning where he's well poised for for that generation.
Marie SchroederSo yeah, that's a really exciting area.
Christian SoschnerGaming is good for boys. I mean, look at Elon Musk. Uh Elon Musk is a gamer. So when I read his biography, he started gaming in his early uh teen years and uh kept it up until then. So your son might be the next uh uh Elon Musk, and maybe he brings uh quantum computing to the market.
Marie SchroederYeah, I'll actually I'll um that's a good place to end on. I'll go pick him up and tell him you said so, and he'll be he'll be very excited about that. So that's that's quite fun.
Christian SoschnerMarie, thank you very much for this uh pleasant conversation. I really enjoyed every minute. Uh, thank you for being so open and sharing your personal story on the podcast. Um, I believe it's very helpful for people in similar situations and um privately and in business, and uh listening to your perspective might help them navigate rough waters that come sometimes in business and life. Thank you. Thank thank you very much for being on my show.
Marie SchroederThank you so much. I also really, really enjoyed every minute. I was sort of wondering how we would fill two hours, but it just sort of flew by. So um thank you very much. It was um uh great fun and yeah, looking forward to to being in touch in the future.
Christian SoschnerLet's stay in touch and have a great afternoon with your son.
Marie SchroederYou too. Bye.
Christian SoschnerBye. Here are three things I take from this conversation. First, decide what good looks like before you run an experiment. Marie learns that question inside no one or discandidate follows every program she funds now. The moment you decide after the data what counts as success, you have stopped investing and started hoping. Second, the team decides. Great science with the wrong people fails every single time.
Christian SoschnerMediocre science with the right people still reaches something of value. Those are her words, and she makes the argument on commercial grounds rather than moral ones, which is why it is worth repeating in a board meeting. A fund that builds companies would rather read raw material than a deck polished for a year, and a no is usually an answer about timing. The Swedish company her team watched for three years is the proof of that.
Christian SoschnerMaurice Page at Nova Holdings is in the show notes. If this conversation was useful, send it to one founder or board member who needs it this week. That single share does more for this show than any algorithm, and it makes the next conversation like this one easier to arrange. Follow the show to get the next episode, and I will see you there.
Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...
The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...
In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...
What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...
What do you do on the morning when there are no good moves left? In March 2001, Ben Horowitz took Loudcloud public in the middle of the dot-com collapse. The bankers cut the price from ten dollars a share to six in the...